Health Care

US biogeneric exclusivity extended?

Proposed US legislation would prohibit biogeneric companies from competing with sales of brand-name biologics for at least 12 years. Should it be passed, we believe this potentially gives brand-name biological drugs so many years of exclusivity that it would not be economically feasible to develop generics.

Key recommendations & forecasts

	Reuters	Year end	Recom	Price	Target price	EPS 1fcst	PE 1fcst
CSL Ltd ¹	CSL.AX	Jun 2010	Hold	A\$31.76	A\$36.30	1.93	16.50
Clinuvel ¹	CUV.AX	Jun 2010	Buy	A\$0.31	A\$0.85	-0.05	n/a
Mesoblast ¹	MSB.AX	Jun 2010	Buy	A\$1.42	A\$1.21	-0.10	n/a

Sector performance

	(1M)	(3M)	(12M)				
Absolute	37.1	65.5	151.6				
Absolute (%)	11.2	21.6	70.1				
Rel market (%)	5.8	13.0	23.7				
ASX All Ordinarias: 4776 70							

BBG AP Health: 367.96 Source: Bloomberg

1. Normalised EPS - pre non-recurring items and post preference dividends

Priced at close 3 December 2009

Source: Company data, RBS forecasts

The biogenerics class of molecules - what are they?

A generic drug is generally a chemical compound, while a biogeneric drug is a generic version of a previously patented drug that is based on a product produced in the body. Biogenerics are not as easy to copy as oral generic drugs. They typically mimic the complex folded shapes of natural proteins, and the molecules of some biologics are thousands of times larger than a typical drug molecule. As a result, going forward the biogenerics industry is thought to have higher barriers to entry than the oral generics market. Therefore, only a small number of generics companies are likely to be able to enter this market.

Congress set to debate a 12-year biogeneric exclusivity period in the US

Health-care overhaul legislation in the US Senate and House would, for the first time, set up an approval process that allows generic-drug firms to develop biogenerics. However, the legislation would prohibit biogeneric companies from competing with sales of brand-name biologics for at least 12 years.

This is longer than previously expected

The 12-year exclusivity period in the US House and Senate bills is longer than the sevenyear exclusivity period that President Obama proposed in his Budget in February. The Senate starts debate next month. If it passes a bill, a House-Senate conference committee would be the final chance to change the exclusivity period. Industry feedback suggests Congress is asking for a new testing standards scheme for any potential biogeneric. We believe this length of exclusivity would give brand-name biological drugs so many years of exclusivity that it might not be economically feasible to develop generics. This would have the effect of protecting brand-name biologics from CSL, CUV and MSB.

CSL is already in the biologicals space with its rFVIII and its R&D projects

For CSL, while we have not changed our assumptions as a result of this news we will continue to monitor the situation, which we believe is relevant for the company's rFVIII (11% of FY10F revenues) and other R&D projects including its GM-CSFR (in Rheumatoid Arthritis) project and Anti-Leukaemia Antibody project. In addition, we believe a positive decision for the brand-name drug producers is a potential positive for CUV, which has developed a biologic called CUV-1647, and for MSB, which is progressing biologic mesenchymal stem cells through clinical trials.

Important disclosures can be found in the Disclosures Appendix.

Analysts

Dr David Stanton

Zara Lvons

RBS Equities (Australia) Limited, ABN 84 002 768 701, AFS Licence 240530 Level 29, RBS Tower, 88 Phillip Street, Sydney NSW 2000, Australia

http://www.abnamroresearch.com

Stretching out the exclusivity period

According to IMS, in 2007, 56% of global biologics sales, or roughly US\$42bn, occurred in the US. Proposed US legislation would prohibit biogeneric companies from competing with sales of brand-name biologics for at least 12 years. Should it be passed, we believe this level of exclusivity gives brand-name biological drugs so many years of exclusivity that it might not be economically feasible to develop generics. This would have the effect of protecting brand-name biologics from CSL, CUV and MSB. In this note, we:

- define biogenerics and biosimilars;
- highlight the market opportunity; and
- describe what it means for CSL, CUV and MSB.

1. Definition of biogenerics/biosimilars

A **biogeneric** drug is a generic version of a previously patented drug that is based on a product produced in the body. Europeans use the term '**biosimilar**' while the FDA speaks of a '**follow-on protein product**'.

Conventional 'small-molecule' drugs are mass-produced in pharmaceuticals manufacturing plants. Biotech products are made by culturing specially engineered bacteria, yeast or human cells. A different production process yields a variant of the original biotech product, not an exact copy. Process variations may change a product's safety or effectiveness.

Biotech pharmaceuticals are not as easy to copy. They typically mimic the complex folded shapes of natural proteins and the molecules of some biologics are thousands of times larger than a typical drug molecule.

2. Large generic players see biogenerics as a driver for growth

Large competitors are trying to get into the biogenerics space. An open biogenerics market would benefit companies such as Sandoz, Teva, Novartis, Barr Pharmaceuticals, India's Wockhardt and Dr. Reddys, and Germany's Stada and Hospira. These firms expect a biogenerics industry to be less competitive and more profitable than the traditional generic business, as the barriers to entry in this market are likely to be higher than in others.

However, it is not easy to get a biogeneric to market

There are two reasons for this:

- Innovator companies are trying to make it tougher to enter this space Innovator companies are adding patents to existing drugs with the aim of increasing the difficulty for new players to enter this space. For instance, Amgen has increased the patent protection around its EPO. The first US patent on Amgen's EPO expired in 2004, but the company has six others that last to 2015. In addition, we expect legal action in this space to increase.
- It is difficult to make these products It is hard to predict how necessary process variations (required to avoid patents) will change a product's safety or effectiveness. Both J&J (with EPO) and Genentech (with Raptiva) suffered lengthy delays when they took over production of the EPO that it sold in international markets.

3. What does this mean for our coverage universe?

CSL does not manufacture its own rFVIII. Rather, Bayer (BAY) manufactures Kogenate, its rFVIII, and CSL rebadges and on-sells this as Helixate. Helixate is used to treat patients with Haemophilia A and makes up 11.0% of CSL's FY10F revenue. Under the terms of a financial agreement, BAY and CSL sell their rFVIII for about the same price. Under the terms of the contract, it is in CSL's interests to sell its rFVIII at the same price as BAY.

In 2007, CSL announced it had concluded an agreement that has extended the arrangements with Bayer (BAY) for the supply of Helixate. The arrangement secured a distribution agreement for a further eight years until the end of 2017.

RBS viewpoint

The 12-year exclusivity period in the US House and Senate bills is longer than the seven-year exclusivity period that President Obama proposed in his Budget in February. The Senate starts debate next month. If it passes a bill, a House-Senate conference committee would be the final chance to change the exclusivity period. Industry feedback suggests Congress is asking for a new testing standards scheme for any potential biogeneric. We believe this level of exclusivity gives brand-name biological drugs so many years of exclusivity that it might not be economically feasible to develop generics. This would have the effect of protecting brand-name biologics from CSL, CUV and MSB.

CSL – financial summary

Income statement	AIFRS 2008A	AIFRS 2009A	AIFRS 2010F	AIFRS 2011F	AIFRS 2012F	Closin Valuat
Divisional sales	3556.7	4622.4	4986.4	5168.5	5543.0	Preferr
Total revenue	3768.2	4976.0	5162.4	5410.2	5851.7	DCF v
EBITDA	1108.4	1526.4	1610.8	1863.5	1979.6	Rf
Associate income	0.0	0.0	0.0	0.0	0.0	Rm-Rf
Depreciation/Amortisation	-141.8	-181.6	-195.9	-203.1	-217.8	Equity
EBITA	966.6	1344.8	1414.9	1660.5	1761.8	CAPM
Goodwill amortisation EBIT	0.0 966.6	0.0 1344.8	0.0 1414.9	0.0 1660.5	0.0 1761.8	E/EV*I
EBIT(incl associate profit)	966.6	1344.8	1414.9	1660.5	1761.8	Equity Debt (I
Net interest expense	-14.6	-5.2	44.0	35.0	67.5	Interes
Pre-tax profit	952.0	1339.6	1458.9	1695.5	1829.3	Tax ra
Income tax expense	-250.2	-319.3	-350.1	-423.9	-457.3	WACC
After-tax profit	701.8	1020.3	1108.8	1271.6	1372.0	
Minority interests	0.0	0.0	0.0	0.0	0.0	
NPAT pre significant items	701.8	1020.3	1108.8	1271.6	1372.0	Multip
Significant items	0.0	125.6	0.0	0.0	0.0	Enterp
Reported NPAT	701.8	1145.9	1108.8	1271.6	1372.0	EV/Sa EV/EB
Divisional sales revenue	2008A	2009A	2010F	2011F	2012F	EV/EB
CSL Behring	2822.4	3786.4	3955.0	4402.3	4730.1	PE (no
CSL Bioplasma	253.3	334.0	357.4	382.4	409.2	PEG (r
CSL Biotherapies	481.0	502.0	674.0	383.7	403.8	
Other revenue Intellectual Property Licensing	26.2 185.3	188.3 165.3	25.0 151.0	25.0 216.7	25.0 283.7	At targ
interestuari roperty Licensing	100.0	103.3	101.0	210.7	203.1	PE (no
Divisional EBIT	2008A	2009A	2010F	2011F	2012F	C
CSL Behring CSL Bioplasma	793.0 38.0	1203.0 50.1	53.6	1389.9 57.4	1422.1 61.4	Comp ResMe
CSL Biotherapies	36.0 24.7	-37.9	20.3	-12.9	-13.5	Year to
Other	-28.4	-37.9	20.5	-12.9	20.3	i cai u
Intellectual Property Licensing	139.3	141.2	142.8	206.6	271.6	
Cash flow statement	2008A	2009A	2010F	2011F	2012F	Cochle Year to
EBITDA	1108.4	1526.4	1610.8	1863.5	1979.6	
Change in working capital	-157.0	-281.3	-137.3	-68.7	-141.3	
Net interest (pd)/rec	-11.4	3.7	44.0	35.0	67.5	
Taxes paid	-237.9	-294.1	-350.1	-423.9	-457.3	Per sh
Other oper cash items	-12.9	70.1	0.0	0.0	0.0	No. sh
Cash flow from ops (1)	689.3	1024.8	1167.3	1406.0	1448.4	EPS (o
Capex (2)	-218.1	-285.6	-320.0	-336.0	-352.8	EPS (r
Disposals/(acquisitions)	-26.0	-30.9	-31.0	0.0	0.0	Divide
Other investing cash flow Cash flow from invest (3)	4.9 -239.1	-133.0 -449.5	0.0 -351.0	0.0 -336.0	0.0 -352.8	Divide Divide
Incr/(decr) in equity	-239.1	1805.0	-1591.0	-330.0	-332.8	Divide
Incr/(decr) in debt	-36.9	-397.3	0.0	0.0	0.0	Growt
Ordinary dividend paid	-227.4	-319.5	-394.5	-402.8	-462.7	Sales
Preferred dividends (4)	0.0	0.0	0.0	0.0	0.0	Opera
Other financing cash flow	26.1	-34.0	0.0	0.0	0.0	EBITD
Cash flow from fin (5)	-225.1	1054.1	-1985.6	-402.8	-462.7	EBITA
Forex and disc ops (6)	0.0	0.0	0.0	0.0	0.0	Divisio
Inc/(decr) cash (1+3+5+6)	225.0	1629.4	-1169.2	667.1	632.9	CSL B
Equity FCF (1+2+4)	471.2	739.2	847.3	1070.0	1095.6	CSL B CSL B
Balance sheet	2008A	2009A	2010F	2011F	2012F	
Cash & deposits	701.6	2528.1	1358.9	2026.0	2658.9	EBIT g
Trade debtors	709.4	885.9	955.6	990.5	1062.3	NPAT
Inventory Investments	1198.1 8.4	1522.0 8.4	1641.9 8.4	1701.8 8.4	1825.2 8.4	Norma EPS g
Goodwill	672.5	758.3	758.3	758.3	758.3	Norma
Other intangible assets	238.0	216.2	191.9	134.5	72.9	Norma
Fixed assets	975.9	1197.5	1377.0	1567.3	1763.9	Opera
Other assets	191.0	250.3	250.3	250.3	250.3	Asset
Total assets	4695.0	7366.8	6542.3	7437.2	8400.3	EBITD
Short-term borrowings	128.1	332.4	332.4	332.4	332.4	EBIT r
Trade payables	444.7	663.8	716.1	742.2	796.0	Net pro
Long-term borrowings	825.1	385.4	385.4	385.4	385.4	Return
Provisions	93.7	108.1	108.1	108.1	108.1	Net de
Other liabilities	397.3	414.3	405.6	444.4	458.1	Net de
Total liabilities Preference shares	1888.8	1903.9	1947.5	2012.4	2080.0	Net int ROIC
Hybrid equity	0.0 0.0	0.0 0.0	0.0 0.0	0.0 0.0	0.0 0.0	NUIC
Share capital	1034.3	2760.2	0.0 1169.2	0.0 1169.2	0.0 1169.2	Intern
Other reserves	-134.3	15.2	15.2	15.2	15.2	Currer
Retained earnings	1906.1	2687.5	3410.4	4240.4	5135.9	Receiv
Other equity	0.0	0.0	0.0	0.0	0.0	Payab
Total equity	2806.1	5462.9	4594.8	5424.8	6320.3	
Minority interest	0.0	0.0	0.0	0.0	0.0	
Total shareholders' equity	2806.1	5462.9	4594.8	5424.8	6320.3	
Total liabilities & SE	4695.0	7366.8	6542.3	7437.2	8400.3	

looing price (At)	31.76	Dei	on torget (A¢)	36.3
Closing price (A\$) /aluation metrics			ce target (A\$)	
Preferred methodology OCF valuation inputs	DCF, EV/EBITDA,	PE \	√al'n (A\$)	\$ 33.00
Rf	5.25%		10-year rate	5.25%
Rm-Rf	6.00%		Margin	2.0%
quity Beta	1.26		<d< td=""><td>7.25%</td></d<>	7.25%
CAPM (Rf+Beta(Rm-Rf))	12.8%		Ke	12.89
E/EV*Ke+D/EV*Kd(1-t)		V cash flow (16408.
quity (E/EV)		nority interest		0.0
		•	(даш)	
ebt (D/EV)		t debt (A\$m)	>	-1810.:
nterest rate		estments (A\$		8.4
ax rate (t)		uity market va		18227.4
VACC		uted no. of sh		575.
	DC	CF valuation (A\$)	31.6
lultiples	2009A	2010F	2011F	2012
interprise value (A\$m)	15479.1	16648.3	15981.2	15348.3
V/Sales (x)	3.3	3.3	3.1	2.
V/EBITDA (x)	10.1	10.3	8.6	7.
V/EBIT (x)	11.5	11.8	9.6	8.
PE (normalised) (x)	18.6	16.5	13.7	12.
PEG (normalised) (x)	1.1	1.0	0.8	0.8
				-
t target price	2009A 11.8	2010F 11.9	2011F 9.9	2012 9.0
PE (normalised) (x)	21.3	18.8	9.9 15.7	9.1
omnarable company data ()		20405	20445	2042
Comparable company data (x)		2010F	2011F	2012
ResMed Inc	EV/EBITDA	12.4	10.2	8.4
'ear to 30 Jun	EV/EBIT	16.0	13.1	10.
	PE	22.7	19.4	16.
	PEG	1.5	1.3	1.
Cochlear	EV/EBITDA	15.7	13.4	12.3
ear to 30 Jun	EV/EBIT	17.3	14.5	13.
	PE	24.1	20.2	18.
	PEG	24.1 1.3	20.2	18.
lo. share data	2009A 601.6	2010F 548.6	2011F 548.6	2012I 548.0
PS (cps)	191.7	192.8	231.8	250.
PS (normalised) (c)	170.7	192.8	231.8	250.
Dividend per share (c)	70.0	67.0	81.0	88.
Dividend payout ratio (%)	41.2	34.8	34.7	34.
Dividend yield (%)	2.2	2.1	2.6	2.
Browth ratios	2009A	2010F	2011F	2012
Sales growth	30.0%	7.9%	3.7%	7.2%
Operating cost growth	26.5%	9.0%	-2.1%	7.8%
BITDA growth	37.7%	5.5%	15.7%	6.2%
BITA growth	39.1%	5.2%	17.4%	6.1%
Divisional EBIT growth				
SL Behring	51.7%	-2.5%	18.5%	2.3%
SL Bioplasma	31.7%	7.0%	7.0%	7.0%
SL Biotherapies	-253.6%	-153.4%	-163.8%	4.4%
BIT growth	39.1%	5.2%	17.4%	6.1%
IPAT growth	45.4%	5.2% 8.7%	14.7%	7.9%
•				
lormalised NPAT growth	45.4%	8.7%	14.7%	7.9%
PS growth lormalised EPS growth	34.6% 34.6%	12.9% 12.9%	20.2% 20.2%	7.9% 7.9%
-				
perating performance	2009A	2010F	2011F	2012
sset turnover (%)	19.2	17.9	18.5	17.
BITDA margin (%)	33.0	33.0	32.3	36.
BIT margin (%)	29.1	29.1	28.4	32.
let profit margin (%)	22.1	22.1	22.2	24.
eturn on net assets (%)	24.6	30.8	30.6	27.9
let debt (A\$m)	-1810.3	-641.1	-1308.2	-1941.
let debt/equity (%)	-33.1	-14.0	-24.1	-30.
let interest/EBIT cover (x) OIC (%)	260.4 29.9	-32.2 26.3	-47.4 28.6	-26. 29.1
	29.9	20.3	20.0	29.
nternal liquidity	2009A	2010F	2011F	2012
Current ratio (v)	4.0	3.1	3.5	4.0
	F 0	F 4	F 0	~
Current ratio (x) Receivables turnover (x) Payables turnover (x)	5.8 5.6	5.4 4.9	5.3 4.5	5.4 4.0

Source: Company data, RBS estimates

CUV – financial summary

Year to 30 Jun (A\$m) Income statement	AIFRS 2008A	AIFRS 2009A	AIFRS 2010F	AIFRS 2011F	AIFRS 2012F	CI Va
Divisional sales	0.0	0.0	0.0	14.6	30.3	Pi
Total revenue	0.0	0.0	0.0	14.6	30.3	D
EBITDA	-17.1	-17.4	-17.9	-8.0	2.9	Rf
Associate income	0.0	0.0	0.0	0.0	0.0	R
Depreciation/Amortisation	-0.8	-0.8	-0.1	-0.1	-0.1	Be
EBITA	-17.9	-18.3	-18.0	-8.1	2.9	C
Goodwill Amortisation	0.0	0.0	0.0	0.0	0.0	E/
EBIT	-17.9 -17.9	-18.3 -18.3	-18.0 -18.0	-8.1 -8.1	2.9 2.9	Ec De
EBIT(incl associate profit) Net interest expense	4.3	2.7	3.8	-0.1	2.9	Int
Pre-tax profit	-13.6	-15.6	-14.3	-5.4	5.8	Та
Income tax expense	0.0	0.0	0.0	0.0	-1.7	w
After-tax profit	-13.6	-15.6	-14.3	-5.4	4.1	
Minority interests	0.0	0.0	0.0	0.0	0.0	
NPAT pre significant items	-13.6	-15.6	-14.3	-5.4	4.1	М
Significant items	-1.0	0.0	0.0	0.0	0.0	Er
Reported NPAT	-14.7	-15.6	-14.3	-5.4	4.1	E/
Cash flow statement	2008A	2009A	2010F	2011F	2012F	E
EBITDA	-17.1	-17.4	-17.9	-8.0	2.9	PE
Change in working capital	0.0	1.8	0.4	0.5	5.4	PE
Net interest (pd)/rec	4.0	2.9	3.8	2.7	2.9	
Taxes paid	0.3	0.2	0.0	0.0	-1.7	At
Other oper cash items	5.6	1.5	0.0	0.0	0.0	E/
Cash flow from ops (1)	-7.2 -0.2	-11.0 0.0	-13.8 -0.2	-4.9 -0.2	9.6 -0.2	PE
Capex (2) Disposals/(acquisitions)	-0.2	0.0	-0.2	-0.2	-0.2	C
Other investing cash flow	0.0	0.0	0.0	0.0	0.0	AI
Cash flow from invest (3)	-0.2	0.0	-0.2	-0.2	-0.2	Ye
Incr/(decr) in equity	0.0	0.1	0.0	0.0	0.0	
Incr/(decr) in debt	0.0	0.0	0.0	0.0	0.0	
Ordinary dividend paid	0.0	0.0	0.0	0.0	0.0	M
Preferred dividends (4)	0.0	0.0	0.0	0.0	0.0	Ye
Other financing cash flow	-0.5	6.6	0.0	0.0	0.0	
Cash flow from fin (5)	-0.5	6.7	0.0	0.0	0.0	
Forex and disc ops (6) Inc/(decr) cash (1+3+5+6)	0.0 -7.9	0.3 -4.0	0.0 -13.9	0.0 -5.1	0.0 9.4	Pe
Equity FCF (1+2+4)	-7.4	-4.0	-13.9	-5.1	9.4 9.4	N
			10.0	0.1	0.1	EF
Balance sheet	2008A	2009A	2010F	2011F	2012F	EF
Cash & deposits	25.8	21.7	7.8	2.7	12.1	Di
Trade debtors	0.6	0.2	0.2	0.3	0.5	Di
Inventory Investments	0.0 0.0	0.0 0.0	0.0 0.0	0.0 0.0	0.0 0.0	Di
Goodwill	0.0	0.0	0.0	0.0	0.0	G
Other intangible assets	1.4	0.0	0.0	0.7	0.0	Sa
Fixed assets	0.4	0.4	0.4	0.5	0.6	O
Other assets	26.8	18.7	18.7	18.7	18.7	E
Total assets	55.0	41.6	27.8	22.8	32.6	E
Short-term borrowings	0.0	0.0	0.0	0.0	0.0	No
Trade payables	3.0	4.4	4.8	5.3	11.0	No
Long-term borrowings	0.0	0.0	0.0	0.0	0.0	_
Provisions Other liabilities	0.0	0.0	0.0	0.0 0.2	0.0	0
Total liabilities	0.2 3.2	0.2 4.6	0.2 5.0	0.2 5.5	0.2 11.2	As Ef
Preference shares	5.2	4.0	5.0	5.5	11.2	E
Hybrid equity						Ne
Share capital	113.2	113.2	113.2	113.2	113.2	Re
Other reserves	1.8	2.2	2.2	2.2	2.2	Ne
Retained earnings	-63.2	-78.3	-92.6	-98.0	-94.0	Ne
Other equity	0.0	0.0	0.0	0.0	0.0	Ne
Total equity	51.8	37.1	22.8	17.4	21.4	R
Minority interest	0.0	0.0	0.0	0.0	0.0	
Total shareholders' equity	51.8	37.1	22.8	17.4	21.4	In
Total liabilities & SE	55.0	41.6	27.8	22.8	32.6	Ci Re
						P

Closing price (A\$)	0.31	Pric	ce target (A\$)		0.85
Valuation metrics Preferred methodology	DCF	V	al'n (A\$)	\$	0.85
DCF valuation inputs	20.		a (7.1¢)	Ŷ	0.00
Rf	6.50%	10)-year rate		6.50%
Rm-Rf	4.50%	M	argin		2.0%
Beta	1.50	K	, E		8.50%
CAPM (Rf+Beta(Rm-Rf))	13.3%	Ke	e		13.2%
E/EV*Ke+D/EV*Kd(1-t)		NPV cash flow	(A\$m)		236.0
Equity (E/EV)	100.0%	Minority interes	t (A\$m)		0.0
Debt (D/EV)		Net debt (A\$m)			-21.
Interest rate		Investments (A	. ,		0.0
Tax rate (t)		Equity market v	(. ,		257.
WACC	13.2%	Diluted no. of shares (m)			303.1
		DCF valuation	(A\$)		0.8
Multiples	2009A	2010F	2011F		2012
Enterprise value (A\$m)	69.2	83.2	88.2		78.
EV/Sales (x)			6.0		2.6
EV/EBITDA (x)	-4.0	-4.6	-11.0		26.
EV/EBIT (x)	-3.8	-4.6	-10.9		27.
PE (normalised) (x)	-5.8	-6.4	-16.8		22.4
PEG (normalised) (x)					
		00405			
At target price EV/EBITDA (x)	2009A -13.5	2010F -13.9	2011F -31.7		2012 83.
PE (normalised) (x)	-13.5	-13.9	-31.7		63.
	-10.5	-10.1	-47.5		00.
Comparable company data	(x)	2010F	2011F		2012
Alchemia	EV/EBITDA	-30.9	9.8		4.
Year to 30 Jun	EV/EBIT	-20.7	12.0		4.
	PE	-24.4	12.2		5.
	PEG	-7.0	3.5		1.
Mesoblast	EV/EBITDA	-15.8	-13.6		52.
Year to 30 Jun	EV/EBIT	-15.7	-13.6		90.
	PE	-14.7	-15.3		-2368.
	PEG				
Per share data	2009A	2010F	2011F		2012
No. shares	303.1	303.1	303.1		303.
EPS (cps)	-5.1	-4.7	-1.8		1.
EPS (normalised) (c)	-5.1	-4.7	-1.8		1.
Dividend per share (c)	0.0	0.0	0.0		0.
Dividend payout ratio (%)	0.0	0.0	0.0		0.
Dividend yield (%)	0.0	0.0	0.0		0.
Growth ratios	2009A	2010F	2011F		2012
Sales growth	na	na	na		n
Operating cost growth	na	na	na		n
EBITDA growth	na	na	na		n
EBIT growth	na	na	na		n
Norm. NPAT growth	na	na	na		n
Norm. EPS growth	na	na	na		n
Operating performance	2009A	2010F	2011F		2012
Asset turnover (%)	0.0	0.0	14.4		27.
EBITDA margin (%)	na	na	-55.1		9.
EBIT margin (%)	na	na	-55.6		9.
Net profit margin (%)	na	na	-37.2		13.
Return on net assets (%)	-49.3	-79.0	-46.7		13.
Net debt (A\$m)	-21.7	-7.8	-2.7		-12.
Net debt/equity (%)	-58.6	-34.2	-15.8		-56.
Net interest/EBIT cover (x)	6.9	4.8	3.0		-1.
ROIC (%)	-49.1	-82.2	-37.9		13.
Internal liquidity	2009A	2010F	2011F		2012
	8.9	5.4	4.0		2.
Current ratio (x)	0.5	0.4			
Receivables turnover (x)	na	0.0	59.7		76.

Source: Company data, RBS estimates

MSB – financial summary

AIFRS 2008A	AIFRS 2009A	AIFRS 2010F	AIFRS 2011F	AIFRS 2012F
0.0	0.0	0.0	0.0	26.7
0.0	0.2	0.2	0.2	26.9
-8.7	-10.0	-10.9	-12.4	3.2
-2.1	-2.9	-2.9	-2.9	-2.9
-0.2	-0.1	-0.1	0.0	-1.3
				1.8
		0.0		0.0
				1.8
				-1.0
				0.9
				-0.1
				0.0
				-0.1
				0.0
				-0.1
				0.0
-10.1	-12.3	-13.2	-14.5	-0.1
2008A	2009A	2010F	2011F	2012F
				3.2
	0.0			0.3
0.8				0.9
				0.0
				0.0
				4.4
				-1.3
				0.0
				0.0
				-1.3
				0.0
				0.0
0.0	0.0	0.0		0.0
0.0	0.0	0.0		0.0
				0.0
				0.0
				0.0
				3.0
-5.5	-8.8	-10.1	-11.4	3.0
2008A	2009A	2010F	2011F	2012F
			25.0	
14.1	16.5	21.4		28.0
0.1	0.3	0.4	0.4	0.5
0.1 0.0	0.3 0.0	0.4 0.0	0.4 0.0	0.5 0.0
0.1 0.0 12.8	0.3 0.0 9.3	0.4 0.0 9.3	0.4 0.0 9.3	0.5 0.0 9.3
0.1 0.0 12.8 0.0	0.3 0.0 9.3 0.0	0.4 0.0 9.3 0.0	0.4 0.0 9.3 0.0	0.5 0.0 9.3 0.0
0.1 0.0 12.8 0.0 0.5	0.3 0.0 9.3 0.0 0.5	0.4 0.0 9.3 0.0 0.4	0.4 0.0 9.3 0.0 0.4	0.5 0.0 9.3 0.0 0.4
0.1 0.0 12.8 0.0 0.5 0.2	0.3 0.0 9.3 0.0 0.5 0.2	0.4 0.0 9.3 0.0 0.4 0.2	0.4 0.0 9.3 0.0 0.4 0.2	0.5 0.0 9.3 0.0 0.4 0.2
0.1 0.0 12.8 0.0 0.5 0.2 0.1	0.3 0.0 9.3 0.0 0.5 0.2 0.1	0.4 0.0 9.3 0.0 0.4 0.2 0.1	0.4 0.0 9.3 0.0 0.4 0.2 0.1	0.5 0.0 9.3 0.0 0.4 0.2 0.1
0.1 0.0 12.8 0.0 0.5 0.2 0.1 27.8	0.3 0.0 9.3 0.0 0.5 0.2 0.1 27.0	0.4 0.0 9.3 0.0 0.4 0.2 0.1 31.9	0.4 0.0 9.3 0.0 0.4 0.2 0.1 35.6	0.5 0.0 9.3 0.0 0.4 0.2 0.1 38.7
0.1 0.0 12.8 0.0 0.5 0.2 0.1 27.8 0.0	0.3 0.0 9.3 0.0 0.5 0.2 0.1 27.0 0.0	0.4 0.0 9.3 0.0 0.4 0.2 0.1 31.9 0.0	0.4 0.0 9.3 0.0 0.4 0.2 0.1 35.6 0.0	0.5 0.0 9.3 0.0 0.4 0.2 0.1 38.7 0.0
0.1 0.0 12.8 0.0 0.5 0.2 0.1 27.8 0.0 1.6	0.3 0.0 9.3 0.0 0.5 0.2 0.1 27.0 0.0 1.2	0.4 0.0 9.3 0.0 0.4 0.2 0.1 31.9 0.0 1.4	0.4 0.0 9.3 0.0 0.4 0.2 0.1 35.6 0.0 1.7	0.5 0.0 9.3 0.0 0.4 0.2 0.1 38.7 0.0 2.0
0.1 0.0 12.8 0.0 0.5 0.2 0.1 27.8 0.0 1.6 0.0	0.3 0.0 9.3 0.0 0.5 0.2 0.1 27.0 0.0 1.2 0.0	0.4 0.0 9.3 0.0 0.4 0.2 0.1 31.9 0.0 1.4 0.0	0.4 0.0 9.3 0.0 0.4 0.2 0.1 35.6 0.0 1.7 0.0	0.5 0.0 9.3 0.0 0.4 0.2 0.1 38.7 0.0 2.0 0.0
$\begin{array}{c} 0.1 \\ 0.0 \\ 12.8 \\ 0.0 \\ 0.5 \\ 0.2 \\ 0.1 \\ 27.8 \\ 0.0 \\ 1.6 \\ 0.0 \\ 0.0 \\ 0.0 \end{array}$	0.3 0.0 9.3 0.0 0.5 0.2 0.1 27.0 0.0 1.2 0.0 0.0	0.4 0.0 9.3 0.0 0.4 0.2 0.1 31.9 0.0 1.4 0.0 0.0	0.4 0.0 9.3 0.0 0.4 0.2 0.1 35.6 0.0 1.7 0.0 0.0	0.5 0.0 9.3 0.0 0.4 0.2 0.1 38.7 0.0 2.0 0.0 0.0
$\begin{array}{c} 0.1 \\ 0.0 \\ 12.8 \\ 0.0 \\ 0.5 \\ 0.2 \\ 0.1 \\ 27.8 \\ 0.0 \\ 1.6 \\ 0.0 \\ 0.0 \\ 0.0 \\ 0.0 \end{array}$	0.3 0.0 9.3 0.0 0.5 0.2 0.1 27.0 0.0 1.2 0.0 0.0 0.0 0.0	0.4 0.0 9.3 0.0 0.4 0.2 0.1 31.9 0.0 1.4 0.0 0.0 2.9	0.4 0.0 9.3 0.0 0.4 0.2 0.1 35.6 0.0 1.7 0.0 0.0 5.7	0.5 0.0 9.3 0.0 0.4 0.2 0.1 38.7 0.0 2.0 0.0 0.0 8.6
$\begin{array}{c} 0.1 \\ 0.0 \\ 12.8 \\ 0.0 \\ 0.5 \\ 0.2 \\ 0.1 \\ 27.8 \\ 0.0 \\ 1.6 \\ 0.0 \\ 0.0 \\ 0.0 \end{array}$	0.3 0.0 9.3 0.0 0.5 0.2 0.1 27.0 0.0 1.2 0.0 0.0	0.4 0.0 9.3 0.0 0.4 0.2 0.1 31.9 0.0 1.4 0.0 0.0	0.4 0.0 9.3 0.0 0.4 0.2 0.1 35.6 0.0 1.7 0.0 0.0	0.5 0.0 9.3 0.0 0.4 0.2 0.1 38.7 0.0 2.0 0.0 0.0
$\begin{array}{c} 0.1 \\ 0.0 \\ 12.8 \\ 0.0 \\ 0.5 \\ 0.2 \\ 0.1 \\ 27.8 \\ 0.0 \\ 1.6 \\ 0.0 \\ 0.0 \\ 0.0 \\ 1.6 \end{array}$	0.3 0.0 9.3 0.5 0.2 0.1 27.0 0.0 1.2 0.0 0.0 0.0 1.2	0.4 0.0 9.3 0.0 0.4 0.2 0.1 31.9 0.0 1.4 0.0 0.0 2.9 4.3	0.4 0.0 9.3 0.0 0.4 0.2 0.1 35.6 0.0 1.7 0.0 0.0 5.7 7.4	0.5 0.0 9.3 0.0 0.4 0.2 0.1 38.7 0.0 2.0 0.0 0.0 0.0 8.6 10.6
$\begin{array}{c} 0.1 \\ 0.0 \\ 12.8 \\ 0.0 \\ 0.5 \\ 0.2 \\ 0.1 \\ 27.8 \\ 0.0 \\ 1.6 \\ 0.0 \\ 0.0 \\ 1.6 \\ 0.0 \\ 1.6 \\ 0.0 \\ \end{array}$	0.3 0.0 9.3 0.0 0.5 0.2 0.1 27.0 0.0 1.2 0.0 0.0 1.2 0.0	0.4 0.0 9.3 0.0 0.4 0.2 0.1 31.9 0.0 1.4 0.0 0.0 2.9 4.3	0.4 0.0 9.3 0.0 0.4 0.2 0.1 35.6 0.0 1.7 0.0 0.0 5.7 7.4	0.5 0.0 9.3 0.0 0.4 0.2 0.1 38.7 0.0 2.0 0.0 0.0 8.6 10.6
0.1 0.0 12.8 0.0 0.5 0.2 0.1 27.8 0.0 1.6 0.0 0.0 1.6 0.0 51.0	0.3 0.0 9.3 0.0 0.5 0.2 0.1 27.0 0.0 1.2 0.0 0.0 0.0 1.2 0.0 62.5	0.4 0.0 9.3 0.0 0.4 0.2 0.1 31.9 0.0 1.4 0.0 0.0 2.9 4.3 0.0 77.5	0.4 0.0 9.3 0.0 0.4 0.2 0.1 35.6 0.0 1.7 0.0 0.0 5.7 7.4 0.0 92.5	0.5 0.0 9.3 0.0 0.4 0.2 0.1 38.7 0.0 2.0 0.0 0.0 8.6 10.6 0.0 92.5
0.1 0.0 12.8 0.0 0.5 0.2 0.1 27.8 0.0 1.6 0.0 0.0 1.6 0.0 51.0 3.8	0.3 0.0 9.3 0.5 0.2 0.1 27.0 0.0 1.2 0.0 0.0 1.2 0.0 62.5 4.2	0.4 0.0 9.3 0.0 0.4 0.2 0.1 31.9 0.0 1.4 0.0 0.0 2.9 4.3 0.0 77.5 4.2	0.4 0.0 9.3 0.0 0.4 0.2 0.1 35.6 0.0 1.7 0.0 0.0 5.7 7.4 0.0 92.5 4.2	0.5 0.0 9.3 0.0 0.4 0.2 0.1 38.7 0.0 2.0 0.0 0.0 0.0 8.6 10.6 0.0 92.5 4.2
$\begin{array}{c} 0.1\\ 0.0\\ 12.8\\ 0.0\\ 0.5\\ 0.2\\ 0.1\\ 27.8\\ 0.0\\ 1.6\\ 0.0\\ 0.0\\ 0.0\\ 1.6\\ 0.0\\ 51.0\\ 3.8\\ -28.6 \end{array}$	0.3 0.0 9.3 0.5 0.2 0.1 27.0 0.0 1.2 0.0 0.0 0.0 1.2 0.0 62.5 4.2 -40.8	0.4 0.0 9.3 0.0 0.4 0.2 0.1 31.9 0.0 1.4 0.0 2.9 4.3 0.0 77.5 4.2 -54.0	0.4 0.0 9.3 0.0 0.4 0.2 0.1 35.6 0.0 1.7 0.0 0.0 5.7 7.4 0.0 92.5 4.2 -68.5	0.5 0.0 9.3 0.0 0.4 0.2 0.1 38.7 0.0 2.0 0.0 0.0 8.6 10.6 0.0 92.5 4.2 -68.6
$\begin{array}{c} 0.1\\ 0.0\\ 12.8\\ 0.0\\ 0.5\\ 0.2\\ 0.1\\ 27.8\\ 0.0\\ 1.6\\ 0.0\\ 0.0\\ 0.0\\ 1.6\\ 0.0\\ 51.0\\ 3.8\\ -28.6\\ 0.0\\ \end{array}$	0.3 0.0 9.3 0.5 0.2 0.1 27.0 0.0 1.2 0.0 0.0 0.0 62.5 4.2 -40.8 0.0	0.4 0.0 9.3 0.0 0.4 0.2 0.1 31.9 0.0 1.4 0.0 0.0 77.5 4.2 -54.0 0.0	0.4 0.0 9.3 0.0 0.4 0.2 0.1 35.6 0.0 1.7 0.0 0.0 5.7 7.4 0.0 92.5 4.2 -68.5 0.0	0.5 0.0 9.3 0.0 0.4 0.2 0.1 38.7 0.0 2.0 0.0 0.0 0.0 0.0 0.0 92.5 4.2 -68.6 0.0
$\begin{array}{c} 0.1\\ 0.0\\ 12.8\\ 0.0\\ 0.5\\ 0.2\\ 0.1\\ 27.8\\ 0.0\\ 1.6\\ 0.0\\ 0.0\\ 0.0\\ 1.6\\ 0.0\\ 51.0\\ 3.8\\ -28.6\\ 0.0\\ 26.2\\ \end{array}$	0.3 0.0 9.3 0.2 0.1 27.0 0.0 1.2 0.0 0.0 1.2 0.0 62.5 4.2 -40.8 0.0 25.8	0.4 0.0 9.3 0.0 0.4 0.2 0.1 31.9 0.0 1.4 0.0 2.9 4.3 0.0 77.5 4.2 -54.0 0.0 27.6	0.4 0.0 9.3 0.0 0.4 0.2 0.1 35.6 0.0 1.7 0.0 0.0 5.7 7.4 0.0 92.5 4.2 -68.5 0.0 28.1	0.5 0.0 9.3 0.0 0.4 0.2 0.1 38.7 0.0 2.0 0.0 0.0 0.0 92.5 4.2 -68.6 0.0 28.0
$\begin{array}{c} 0.1 \\ 0.0 \\ 12.8 \\ 0.0 \\ 0.5 \\ 0.2 \\ 0.1 \\ 27.8 \\ 0.0 \\ 1.6 \\ 0.0 \\ 0.0 \\ 1.6 \\ 0.0 \\ 51.0 \\ 3.8 \\ -28.6 \\ 0.0 \\ 51.0 \\ 3.8 \\ -28.6 \\ 0.0 \\ 26.2 \\ 0.0 \end{array}$	0.3 0.0 9.3 0.0 0.5 0.2 0.1 27.0 0.0 1.2 0.0 0.0 1.2 0.0 62.5 4.2 -40.8 0.0 25.8 0.0	0.4 0.0 9.3 0.0 0.4 0.2 0.1 31.9 0.0 1.4 0.0 0.0 2.9 4.3 0.0 77.5 4.2 -54.0 0.0 27.6 0.0	0.4 0.0 9.3 0.0 0.4 0.2 0.1 35.6 0.0 1.7 7.4 0.0 92.5 4.2 -68.5 0.0 28.1 0.0	0.5 0.0 9.3 0.0 0.4 0.2 0.1 38.7 0.0 2.0 0.0 0.0 92.5 4.2 -68.6 0.0 92.5 4.2 -68.0 0.2 8.0 0.0
$\begin{array}{c} 0.1\\ 0.0\\ 12.8\\ 0.0\\ 0.5\\ 0.2\\ 0.1\\ 27.8\\ 0.0\\ 1.6\\ 0.0\\ 0.0\\ 0.0\\ 1.6\\ 0.0\\ 51.0\\ 3.8\\ -28.6\\ 0.0\\ 26.2\\ \end{array}$	0.3 0.0 9.3 0.2 0.1 27.0 0.0 1.2 0.0 0.0 1.2 0.0 62.5 4.2 -40.8 0.0 25.8	0.4 0.0 9.3 0.0 0.4 0.2 0.1 31.9 0.0 1.4 0.0 2.9 4.3 0.0 77.5 4.2 -54.0 0.0 27.6	0.4 0.0 9.3 0.0 0.4 0.2 0.1 35.6 0.0 1.7 0.0 0.0 5.7 7.4 0.0 92.5 4.2 -68.5 0.0 28.1	0.5 0.0 9.3 0.0 0.4 0.2 0.1 38.7 0.0 2.0 0.0 0.0 0.0 92.5 4.2 -68.6 0.0 28.0
	2008A 0.0 -8.7 -2.1 -0.2 -8.8 0.0 -8.8 -11.0 0.9 -10.1 0.0 -5.4 0.0 0.0 0.0 -5.4 0.0 0.0 0.0 -5.5 2008A	2008A 2009A 0.0 0.0 0.0 0.2 -8.7 -10.0 -2.1 -2.9 -0.2 -0.1 -8.8 -10.1 0.0 0.0 -8.8 -10.1 -1.0 0.0 -8.8 -10.1 -11.0 -12.3 0.0 0.0 -10.1 -12.3 0.0 0.0 -10.1 -12.3 0.0 0.0 -10.1 -12.3 0.0 0.0 -10.1 -12.3 0.0 0.0 -10.1 -12.3 0.0 0.0 -10.1 -12.3 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0	2008A 2010F 0.0 0.0 0.0 0.0 0.2 0.2 -8.7 10.0 -10.9 -2.1 -2.9 -2.9 -0.2 -0.1 -0.1 -8.8 -10.1 -11.0 0.0 0.0 0.0 -8.8 -10.1 -11.0 -10.9 0.0 0.0 -8.8 -10.1 -11.0 -11.0 -13.0 -13.2 0.0 0.0 0.0 -10.1 -12.3 -13.2 0.0 0.0 0.0 -10.1 -12.3 -13.2 0.0 0.0 0.0 -10.1 -12.3 -13.2 0.0 0.0 0.0 -10.1 -12.3 -13.2 0.0 0.0 0.0 -10.1 -12.3 -13.2 0.0 0.0 0.2 0.8 0.7 0.7 0.0	2008A 2009A 2010F 2011F 0.0 0.0 0.0 0.0 0.0 0.2 0.2 0.2 -8.7 -10.0 -10.9 -12.4 -2.1 -2.9 -2.9 -2.9 -0.2 -0.1 -0.1 0.0 -8.8 -10.1 -11.0 -12.4 0.0 0.0 0.0 0.0 -8.8 -10.1 -11.0 -12.4 0.0 0.0 0.0 0.0 -8.8 -10.1 -11.0 -12.4 -11.0 -12.3 -13.2 -14.5 0.0 0.0 0.0 0.0 -10.1 -12.3 -13.2 -14.5 0.0 0.0 0.0 0.0 0.0 -10.1 -12.3 -13.2 -14.5 0.0 0.0 0.0 0.0 0.0 -10.1 -12.3 -13.2 -14.5 0.0 0.0 0.0

Closing price (AS) 1.42 Price target (AS) 1.21 Valuation inputs Valn (AS) \$ 1.21 Rr 5.25% 10.year rate 5.25% Rm-RI 6.00% Margin 2.0% Beta 1.50 Kd 7.25% CAPM (RH-Beta(Rm-RI)) 14.2% Ke 14.2% EV:Yke-D/EVKd1-1 NPV cash flow (ASm) 100 Debt (D/EV) 100.0% Minorthy interest (ASm) 0.0 Debt (D/EV) 0.00% Equity market value (ASm) 166 Interest rate 7.25% Investments (ASm) 100 WACC 117.7 15.8 -13.6 EV/EBITDA (x) -17.7 -15.8 -13.6 52.1 EV/EBITDA (x) -17.7 -15.3 -208.7 2019F 2012F EV/EBITDA (x) -17.7 -15.3 -21.6 -23.2 -20.3 PEG (normalised) (x) -14.9 -13.3 -11.4 43.5 PEG normalised (x) 1010F 2011F 2012F A					
DCF valuation inputs S. 25% 10-year rate 5.25% Rm-Rf 6.00% Margin 2.0% Beta 1.50 Kd 7.25% CAPM (RFHebta(Rm-Rf)) 14.2% Ke 14.2% E/EV/Ket-D/EV/Kd(1-1) NFV cash flow (ASm) 166.1 Equity (E/EV) 100.0% Mindity interest (ASm) 0.0 Debt (D/EV) 100.0% Mindity interest (ASm) 0.0 Tax rate (1) 30.0% Equity market value (ASm) 166.6 WACC 14.2% Diluted no. of shares (m) 137.3 DEF valuation (AS) 121 62.5 EV/Ester Tax 167.5 -13.6 52.1 EV/Ester Tax -17.7 -15.8 -36.6 52.1 EV/Ester Tax -17.7 -15.8 -31.6 52.1 EV/Ester Tax -17.7 -15.8 -31.6 52.1 EV/Ester Tax -17.7 -15.8 -32.6 52.1 EV/Ester Tax -17.7 -15.8 -20.4 12.2 -20.2 -20.2 -20.2 <	Closing price (A\$) Valuation metrics	1.42	Pr	ice target (A\$)	1.21
Rrf 5.25% 10-year rate 5.25% Rm-Rf 6.00% Margin 2.0% Beta 1.50 Kd 7.25% CAPM (Rf+Beta(Rm-Rf)) 14.2% Ke 14.2% Equity (CEV) 100.0% Minority interest (ASm) 0.0 Debt (D/EV) 0.0% Ke debt (ASm) 166.5 Interest rate 7.25% Investments (ASm) 0.0 Tax rate (1) 30.0% Equity market value (ASm) 166.5 VACC 14.2% DUE to // 17.7 176.8 EVISEINTOA (x) -17.7 -15.8 -13.6 62.1 EVISEINTOA (x) -17.7 -15.8 -13.6 62.1 EVIEBITDA (x) -17.7 -15.8 -13.6 62.1 EVIEBITDA (x) -14.3 -14.7 -15.3 -2368.7 PEG (normalised) (x) -14.2 2.101F 2012F 2012F EVIEBITDA (x) -12.2 -12.6 -3.02.7 7 Comparable company data (x) -24.4 12.2 5.7 <td< td=""><td></td><td>DCF</td><td>١</td><td>/al'n (A\$)</td><td>\$ 1.21</td></td<>		DCF	١	/al'n (A\$)	\$ 1.21
Rm-Rf 6.00% Margin 2.0% Beta 1.50 Kd 7.25% CAPM (RH-Beta(Rm-Rf)) 14.2% Ke 14.2% ELEV-Ke+D/EV-Kd(1-t) NPV cash flow (A\$m) 150.1 Equity (E/EV) 0.00% Minotity interest (A\$m) 0.0 Debt (D/EV) 0.0% Net debt (A\$m) 165.5 Interest rate 7.25% investments (A\$m) 0.0 Tax rate (t) 30.0% Equity marker value (A\$m) 166.6 WACC 14.2% Diluted no. of shares (m) 137.3 DCF valuation (A\$) 121 108.5 105.5 EV/EBITDA (x) -17.7 15.8 -13.6 90.4 EV/EBITDA (x) -14.3 -14.7 -15.3 -208.7 PEG (normalised) (x) -14.9 -13.3 -11.4 43.5 PE (normalised) (x) -14.2 -12.6 -13.2 -202.7 Alterget price 2009A 2010F 2011F 2012F Alterget price 0.13.3 -11.4 43.5 <td>-</td> <td>5.05%</td> <td></td> <td>0</td> <td>5.05%</td>	-	5.05%		0	5.05%
Beta 1.50 Kd 7.25% CAPM (Rf+Bata(m-Rf)) 14.2% Ke 14.2% Equity (E/EV) 100.0% Minority interest (ASm) 0.0 Debt (D/EV) 0.0% Net debt (ASm) 166.5 Interest rate 7.25% Investments (ASm) 166.5 WACC 14.2% Diluted no. of shares (m) 137.3 WACC 14.2% Diluted no. of shares (m) 137.3 DCF valuation (AS) 1.21 Mutiples 2009A 2010F 2011F EVISEITDA (x) -17.7 -15.8 -13.6 52.1 EV/EBITDA (x) -17.7 -15.8 -13.6 52.1 EV/EBITDA (x) -17.7 -15.3 -208.7 2038.7 PE (normalised) (x) -14.3 -14.7 -15.3 -2032.7 Comparable company data (x) 2010F 2011F 2012F EV/EBITDA (x) -14.2 -13.2 -2032.7 Comparable company data (x) 2010F 2011F 2012F Alchemia EV/EBITDA -2.6 <t< td=""><td></td><td></td><td></td><td>•</td><td></td></t<>				•	
CAPM (R+Beta(Rm-Rf)) 14.2% Ke 14.2% Ke 14.2% E/EV/Ke+D/EV/Kd(1+1) NPV cash flow (A\$m) 150.1 Equity (E/EV) 0.0% Minority interest (A\$m) 0.0 Debt (D/EV) 0.0% Net debt (A\$m) 16.5 Interest rate 7.25% investments (A\$m) 10.6 WACC 14.2% Ditted no. of shares (m) 13.3 DCF valuation (A\$) 17.1 168.5 165.5 EV/Esite (X) -17.7 -15.8 -13.6 90.4 EV/Esite (X) -14.9 13.3 -11.4 43.5 PE (normalised) (x) -14.9 -30.9 9.8 4.1 Year to 30 Jun EV/EBIT A -30.9 9.8 4.1 Year to 30 Jun EV/EBIT - 20.27 12.0 4.7 Year to 30 Jun EV/EBIT - 20.6				-	
Equity (EEV) 100.0% Minority interest (A\$m) 0.0 Debt (DFV) 0.0% Net debt (A\$m) 16.5 Interest rate 7.25% Investments (A\$m) 100.0% Tax rate (t) 30.0% Equity market value (A\$m) 116.5 WACC 14.2% Diluted n.o. of shares (m) 127.3 Multiples 2009A 2010F 2011F 2012F Enterprise value (A\$m) 177.0 172.1 166.5 162.5 EV/EBITDA (x) -17.7 -15.8 -13.6 90.4 PE (normalised) (x) -14.3 -14.7 -15.3 -2388.7 PE (normalised) (x) -14.9 -13.3 -11.4 43.5 PE (normalised) (x) -12.2 -12.6 -202.7 2002F Comparable company data (x) 2010F 2011F 2012F Alchemia EV/EBITDA -30.9 9.8 4.1 Year to 30 Jun EV/EBIT -2.6 -2.6 5.5 Year to 30 Jun EV/EBIT -2.6 -2.6 5.5 Year to 30 Jun	CAPM (Rf+Beta(Rm-Rf))	14.2%			
Debt (DEV) 0.0% Net debt (ASm) -16.5 Interest rate 7.25% Investments (ASm) 0.0 Tax rate (t) 30.0% Equity market value (ASm) 166.6 WACC 14.2% Diluted no. of shares (m) 137.3 DCF valuation (AS) 121 Mutiples 2009A 2010F 2011F 2012F Enterprise value (ASm) 177.0 172.1 168.5 165.5 EV/Sales (x) -17.7 -15.8 -13.6 90.4 EV/EBITDA (x) -17.5 -15.7 -13.6 90.4 EV/EBITDA (x) -14.9 -13.3 -11.4 43.5 PEG (normalised) (x) -14.9 -13.3 -11.4 43.5 EV/EBITDA (x) -14.9 -13.3 -11.4 43.5 PEG (normalised) (x) -12.2 -12.6 -20.6 5.5 PEG -7.0 3.5 1.6 Tissue Therapies EV/EBITDA -2.6 -2.6 5.5 PE -3.1 -3.6 9.6 9.2	E/EV*Ke+D/EV*Kd(1-t)		NPV cash flow	v (A\$m)	150.1
Interest rate 7.25% Investments (A\$m) 0.0 Tax rate (1) 30.0% cajuly market value (A\$m) 166.6 WACC 14.2% Diluted no.0 shares (m) 187.3 DCF valuation (A\$) 1211 Mutiples 2009A 2010F 2011F 2012F Enterprise value (A\$m) 177.0 172.1 186.5 185.5 EV/EBITDA (x) -17.7 -15.8 -13.6 90.4 PE (normalised) (x) -14.3 -14.7 -15.3 -2368.7 PE (normalised) (x) -14.9 -13.3 -11.4 43.5 PE (normalised) (x) -14.9 -13.3 -11.4 43.5 PE (normalised) (x) -12.2 210.6F 2011F 2012F Alchemia EV/EBIT -20.0 12.0 4.7 Year to 30 Jun EV/EBIT -2.6 2.6 5.5 Year to 30 Jun EV/EBIT -2.6 2.6 5.5 Year to 30 Jun EV/EBIT -2.6 2.6 5.5				, ,	
Tax rate (t) 30.0% Equity market value (A\$m) 166.6 WACC 12.2% DicF valuation (A\$) 1.21 Multiples 2009A 2010F 2011F 2012F Enterprise value (A\$m) 17.70 17.21 166.5 165.5 EV/Sales (x) -17.7 -15.8 -13.6 6.2 EV/EBITDA (x) -17.7 -15.8 -13.6 9.04 PEG (normalised) (x) -14.3 -14.7 -15.3 -2368.7 PEG (normalised) (x) -14.3 -14.7 -15.3 -2368.7 PE (normalised) (x) -14.9 -13.3 -11.4 2012F Alchemia EV/EBITDA -30.9 9.8 4.1 Year to 30 Jun EV/EBITDA -30.9 9.8 4.1 Year to 30 Jun EV/EBITDA -2.6 -2.6 5.5 PE -2.4.4 12.2 2.01 PE -2.4.4 12.2 -0.1 No. shares 12.4.2 150.3 164.5 1164.5 164.5 <			,	,	
WACC 14.2% Diluted no. of shares (m) DCF valuation (AS) 137.3 1.21 Multiples 2009A 2010F 2011F 2012F Enterprise value (ASm) 177.0 172.1 168.5 165.5 EV/Sales (x) -17.7 -15.8 -13.6 90.4 PE (normalised) (x) -14.3 -14.7 -15.3 -2368.7 PEG (normalised) (x) -14.9 -13.3 -11.4 43.5 PE (normalised) (x) -14.9 -13.3 -11.4 43.5 PE (normalised) (x) -12.2 12.6 -13.2 -2032.7 Comparable company data (x) 2010F 2011F 2012F Alchemia EV/EBITDA -30.9 9.8 4.1 Year to 30 Jun EV/EBIT -2.6 -2.6 5.5 PEG -3.1 -3.6 9.6 -9.2 -0.1 Dividend pars share (c) 0.0 0.0 0.0 0.0 0.0 0.0 Dividend payout ratio (%) 0.0 0.0 0.0			,	,	
Multiples 2009A 2010F 2011F 2012F Enterprise value (ASm) 177.0 172.1 168.5 1165.5 EV/Sales (x) -17.7 -15.8 -13.6 6.2 EV/EBIT (x) -17.7 -15.8 -13.6 6.2 EV/EBIT (x) -17.7 -15.8 -13.6 6.2 EV/EBIT (x) -17.7 -15.8 -13.6 90.7 PEG (normalised) (x) -14.3 -14.7 -15.3 -2368.7 PE (normalised) (x) -12.2 12.6 -13.2 -2002.7 Comparable company data (x) 2010F 2011F 2012F Alchemia EV/EBITDA -30.9 9.8 4.1 Year to 30 Jun EV/EBIT -2.0 12.0 4.7 PEG -7.0 3.5 16.5 5.5 Year to 30 Jun EV/EBIT -2.6 -2.6 5.5 PEG -3.1 -3.6 9.6 -9.2 -0.1 Dividend payout ratio (%) 0.0	.,			· · ·	
Enterprise value (A\$m) 177.0 172.1 168.5 165.5 EV/EBITDA (x) -17.7 -15.8 -13.6 52.1 EV/EBITDA (x) -17.7 -15.7 -13.6 90.4 PE (normalised) (x) -14.3 -14.7 -15.3 -2368.7 PEG (normalised) (x) -14.9 -13.3 -11.4 43.5 PE (normalised) (x) -14.9 -13.3 -11.4 43.5 PE (normalised) (x) -12.2 -12.6 -13.2 -2032.7 Comparable company data (x) 2010F 2011F 2012F Alchemia EV/EBITDA -30.9 9.8 4.1 Year to 30 Jun EV/EBITDA -30.9 9.8 4.1 Year to 30 Jun EV/EBITDA -2.6 -2.6 5.5 PEG -7.0 3.5 1.6 1.64.5 164.5 No. shares 124.2 150.3 164.5 164.5 164.5 PEG -3.1 -3.6 9.6 -9.2 -0.1 <th></th> <th></th> <th>DCF valuatio</th> <th>n (A\$)</th> <th>1.21</th>			DCF valuatio	n (A\$)	1.21
EV/Sales (x) 6.2 EV/EBITDA (x) -17.7 -15.8 -13.6 90.4 PE (normalised) (x) -14.3 -14.7 -15.7 -13.6 90.4 PE (normalised) (x) -14.3 -14.7 -15.3 -2368.7 PEG (normalised) (x) -14.9 -13.3 -11.4 43.5 PE (normalised) (x) -12.2 -12.6 -13.2 -2032.7 Comparable company data (x) 2010F 2011F 2012F Alchemia EV/EBIT - 20.7 12.0 4.1 Year to 30 Jun EV/EBIT -2.0 7.0 3.5 1.6 Tissue Therapies EV/EBIT -2.6 -2.6 5.5 PE -3.1 -3.6 9.6 PEG -7.0 3.0 164.5 164.5 164.5 164.5 PEG -3.1 -3.6 9.6 -9.2 -0.1 Dividend payout ratio (%) 0.0 0.0 0.0 0.0 0.0 Dividend payout ratio (%) 0.0 <	Multiples	2009A	2010F	2011F	2012F
EV/EBITDA (x) -17.7 -15.8 -13.6 52.1 EV/EBIT (x) -17.5 -15.7 -13.6 90.4 PE (normalised) (x) -14.3 -14.7 -15.3 -2368.7 PEG (normalised) (x) -14.9 -13.3 -11.4 43.5 PE (normalised) (x) -12.2 -12.6 -13.2 -2032.7 Comparable company data (x) 2010F 2011F 2012F Alchemia EV/EBITDA -30.9 9.8 4.1 Year to 30 Jun EV/EBITDA -30.9 9.8 4.1 Year to 30 Jun EV/EBIT -20.7 12.0 4.7 PE co -7.0 3.5 1.6 5.5 Year to 30 Jun EV/EBIT -2.6 -2.6 5.5 PE co -3.1 -3.6 9.6 -9.2 -0.1 Dividend payout ratio (%) 0.0 0.0 0.0 0.0 0.0 0.0 Dividend payout ratio (%) 0.0 0.0 0.0 0.0 0.0 <td>• • • •</td> <td>177.0</td> <td>172.1</td> <td>168.5</td> <td></td>	• • • •	177.0	172.1	168.5	
EV/EBIT (x) -17.5 -15.7 -13.6 90.4 PE (normalised) (x) -14.3 -14.7 -15.3 -2368.7 PEG (normalised) (x) -14.9 -13.3 -11.4 43.5 PE (normalised) (x) -12.2 -12.6 -13.2 -2032.7 Comparable company data (x) 2010F 2011F 2012F Alchemia EV/EBITDA -30.9 9.8 4.1 Year to 30 Jun EV/EBIT -20.7 12.0 4.7 PE - 24.4 12.2 5.7 -7 2.6 -2.6 5.5 Year to 30 Jun EV/EBIT - 2.6 -2.6 5.5 -7 -3.1 -3.6 9.6 PEG -3.1 -2.6 -2.6 5.5 -7 -7 -7.0 0.0	.,	47.7	45.0	10.0	
PE (normalised) (x) -14.3 -14.7 -15.3 -2368.7 PEG (normalised) (x) -14.9 -13.3 -11.4 43.5 At target price 2009A 2010F 2011F 2012F EV/EBITDA (x) -12.2 -12.6 -13.2 -2032.7 Comparable company data (x) 2010F 2011F 2012F Alchemia EV//EBITDA -30.9 9.8 4.1 Year to 30 Jun EV//EBIT -20.7 12.0 4.7 PE - -24.4 12.2 5.7 Tissue Therapies EV//EBIT -2.6 -2.6 5.5 Year to 30 Jun EV//EBIT -2.6 -2.6 5.5 PE - -3.1 -3.6 9.6 -9.2 -0.1 Dividend payout ratio (c) -9.9 -9.6 -9.2 -0.1 Dividend payout ratio (%) 0.0 0.0 0.0 0.0 Dividend payout ratio (%) 0.0 0.0 0.0 0.0 Sales growth na					
PEG (normalised) (x) At target price 2009A 2010F 2011F 2012F EV/EBITDA (x) -14.9 -13.3 -11.4 43.5 PE (normalised) (x) -12.2 -12.6 -13.2 -2032.7 Comparable company data (x) 2010F 2011F 2012F Alchemia EV/EBITDA -30.9 9.8 4.1 Year to 30 Jun EV/EBIT -20.7 12.0 4.7 PE -24.4 12.2 5.7 FEG -7.0 3.5 1.6 Tissue Therapies EV/EBITDA -2.6 -2.6 5.5 PE -3.1 -3.6 9.6 PEG -3.1 -3.6 9.6 -9.2 -0.1 EV/EBIT 20.0 0.0	.,				
EV/EBITDA (x) -14.9 -13.3 -11.4 43.5 PE (normalised) (x) -12.2 -12.6 -13.2 -2032.7 Comparable company data (x) 2010F 2011F 2012F Alchemia EV/EBITDA -30.9 9.8 4.1 Year to 30 Jun EV/EBITDA -30.9 9.8 4.1 Year to 30 Jun EV/EBITDA -26. -2.6 5.5 Year to 30 Jun EV/EBIT -2.6 -2.6 5.5 Year to 30 Jun EV/EBIT -2.6 -2.6 5.5 Year to 30 Jun EV/EBIT -2.6 -2.6 5.5 PEG -9.9 -9.6 -9.2 -0.1 EPS (normalised) (c) -9.9 -9.6 -9.2 -0.1 Dividend parshare (c) 0.0 0.0 0.0 0.0 0.0 Dividend payout ratio (%) 0.0 0.0 0.0 0.0 0.0 Dividend payout ratio (%) 0.0 0.0 0.0 0.0 0.0	, ,,,				
PE (normalised) (x) -12.2 -12.6 -13.2 -2032.7 Comparable company data (x) 2010F 2011F 2012F Alchemia EV/EBITDA -30.9 9.8 4.1 Year to 30 Jun EV/EBIT -20.7 12.0 4.7 PEG -7.0 3.5 1.6 Tissue Therapies EV/EBITDA -2.6 -2.6 5.5 Year to 30 Jun EV/EBIT -2.6 -2.6 5.5 Year to 30 Jun EV/EBIT -2.6 -2.6 5.5 PE -3.1 -3.6 9.6 9.2 -0.1 No. shares 124.2 150.3 164.5 164.5 EPS (cps) -9.9 -9.6 -9.2 -0.1 Dividend payout ratio (%) 0.0 0.0 0.0 0.0 Dividend payout ratio (%) 0.0 0.0 0.0 0.0 Dividend payout ratio (%) 0.0 0.0 0.0 0.0 Bales growth na na na	At target price				 2012F
Comparable company data (x) 2010F 2011F 2012F Alchemia EV/EBITDA -30.9 9.8 4.1 Year to 30 Jun EV/EBIT -20.7 12.0 4.7 PE -24.4 12.2 5.7 PEG -7.0 3.5 1.6 Tissue Therapies EV/EBITDA -2.6 -2.6 5.5 Year to 30 Jun EV/EBIT -2.6 -2.6 5.5 Year to 30 Jun EV/EBIT -2.6 -2.6 5.5 PE -3.1 -3.6 9.6 -9.2 -0.1 EPS (pos) -9.9 -9.6 -9.2 -0.1 EPS (normalised) (c) -9.9 -9.6 -9.2 -0.1 Dividend payout ratio (%) 0.0 0.0 0.0 0.0 Dividend payout ratio (%) 0.0 0.0 0.0 0.0 Dividend payout ratio (%) 0.0 0.0 0.0 0.0 Dividend payout ratio (%) 0.0 0.0 0.0 0.0<	. ,				
Alchemia EV/EBITDA -30.9 9.8 4.1 Year to 30 Jun EV/EBIT -20.7 12.0 4.7 PE -24.4 12.2 5.7 PEG -7.0 3.5 1.6 Tissue Therapies EV/EBITDA -2.6 -2.6 5.5 Year to 30 Jun EV/EBIT -2.6 -2.6 5.5 Year to 30 Jun EV/EBIT -2.6 -2.6 5.5 Year to 30 Jun EV/EBIT -2.6 -2.6 5.5 PE -3.1 -3.6 9.6 -9.2 -0.1 Dividend per share (c) 0.0 0.0 0.0 0.0 0.0 Dividend payout ratio (%) 0.0 0.0 0.0 0.0 0.0 Dividend yield (%) 0.0 0.0 0.0 0.0 0.0 Growth ratios 2009A 2010F 2011F 2012F Sales growth 15.2% 8.6% 14.2% 89.7% BITA growth 14.5%	PE (normalised) (x)	-12.2	-12.6	-13.2	-2032.7
Year to 30 Jun EV/EBIT -20.7 12.0 4.7 PE -24.4 12.2 5.7 PEG -7.0 3.5 1.6 Tissue Therapies EV/EBITDA -2.6 -2.6 5.5 Year to 30 Jun EV/EBIT -2.6 -2.6 5.5 PE -3.1 -3.6 9.6 PS (ops) -9.9 -9.6 -9.2 -0.1 Dividend per share (c) 0.0 0.0 0.0 0.0 Dividend per share (c) 0.0 0.0 0.0 0.0 Dividend payout ratio (%) 0.0 0.0 0.0 0.0 Dividend yield (%) 0.0 0.0 0.0 0.0 Operating cost growth 15.2% 8.6% 14.2% na EBITD Agrowth 14.5% 8.5% 13.0% na BBITA growth 14.5% 8.5% 13.0% na Norm. NPAT growth 12.3% -2.9% -4.3% na Norm. NPAT gro					
PE -24.4 12.2 5.7 Tissue Therapies EV/EBITDA -2.6 -2.6 5.5 Year to 30 Jun EV/EBIT -2.6 -2.6 5.5 PE -3.1 -3.6 9.6 PEG -3.1 -3.6 9.6 PEG -9.9 -9.6 -9.2 -0.1 EPS (cps) -9.9 -9.6 -9.2 -0.1 Dividend per share (c) 0.0 0.0 0.0 0.0 Dividend payout ratio (%) 0.0 0.0 0.0 0.0 Dividend yiel (%) 0.0 0.0 0.0 0.0 Dividend yiel (%) 0.0 0.0 0.0 0.0 Growth ratios 2009A 2010F 2011F 2012F Sales growth 15.2% 8.6% 14.2% ma BBIT growth 14.5% 8.5% 13.0% na BBIT growth 14.5% 8.5% 13.0% na Norm. NPAT growth (pre GW) 1					
PEG -7.0 3.5 1.6 Tissue Therapies EV/EBITDA -2.6 -2.6 5.5 Year to 30 Jun EV/EBIT -2.6 -2.6 5.5 PE -3.1 -3.6 9.6 PEG -3.1 -3.6 9.6 PS (ormalised) (c) -9.9 -9.6 -9.2 -0.1 Dividend per share (c) 0.0 0.0 0.0 0.0 Dividend payout ratio (%) 0.0 0.0 0.0 0.0 Dividend yield (%) 0.0 0.0 0.0 0.0 0.0 Growth ratios 2009A 2010F 2011F 2012F Sales growth na na na na Operating cost growth 15.2% 8.6% 14.2% 89.7% EBITA growth 14.5% 8.5% 13.0% na Norm. NPAT growth 14.5% 8.5% 13.0% na Norm. NPAT growth (pre GW) 22.1% 7.3% 9.7% -99.3%	real to so suit				
Year to 30 Jun EV/EBIT PE PEG -2.6 -3.1 -2.6 -3.1 -2.6 -3.6 5.5 9.6 Per share data 2009A 2010F 2011F 2012F No. shares 124.2 150.3 164.5 164.5 EPS (cps) -9.9 -9.6 -9.2 -0.1 Dividend pershare (c) 0.0 0.0 0.0 0.0 Dividend payout ratio (%) 0.0 0.0 0.0 0.0 Dividend payout ratio (%) 0.0 0.0 0.0 0.0 Growth ratios 2009A 2010F 2011F 2012F Sales growth na na na na Operating cost growth 15.2% 8.6% 14.2% 89.7% EBITDA growth 14.5% 8.5% 13.0% na Norm. NPAT growth 14.5% 8.5% 13.0% na Norm. NPAT growth (pre GW) 22.1% 7.3% 9.7% -99.3% Norm. NPAT growth 12.3% -2.9% 4.3% na					
PE PEG -3.1 -3.6 9.6 Per share data 2009A 2010F 2011F 2012F No. shares 124.2 150.3 164.5 164.5 EPS (pos) -9.9 -9.6 -9.2 -0.1 EPS (normalised) (c) -9.9 -9.6 -9.2 -0.1 Dividend per share (c) 0.0 0.0 0.0 0.0 Dividend payout ratio (%) 0.0 0.0 0.0 0.0 Dividend yield (%) 0.0 0.0 0.0 0.0 Growth ratios 2009A 2010F 2011F 2012F Sales growth na na na na Operating cost growth 15.2% 8.6% 14.2% 89.7% EBITA growth 14.5% 8.5% 13.0% na BBIT growth 14.5% 8.5% 13.0% na Norm. NPAT growth (pre GW) 22.1% 7.3% 9.7% -99.3% Norm. EPS growth (pre GW) 12.3% -2.9%	Tissue Therapies	EV/EBITDA	-2.6	-2.6	5.5
PEG Per share data 2009A 2010F 2011F 2012F No. shares 124.2 150.3 164.5 164.5 EPS (cps) -9.9 -9.6 -9.2 -0.1 Dividend per share (c) 0.0 0.0 0.0 0.0 Dividend payout ratio (%) 0.0 0.0 0.0 0.0 Dividend payout ratio (%) 0.0 0.0 0.0 0.0 Growth ratios 2009A 2010F 2011F 2012F Sales growth na na na na Operating cost growth 15.2% 8.6% 14.2% 89.7% EBITDA growth 14.5% 8.5% 13.0% na BIT growth 14.5% 8.5% 13.0% na Norm. NPAT growth (pre GW) 22.1% 7.3% 9.7% -99.3% Norm. EPS growth 12.3% -2.9% -4.3% na Norm. EPS growth 12.3% -2.9% -4.3% na N	Year to 30 Jun				5.5
No. shares124.2150.3164.5164.5EPS (cps)-9.9-9.6-9.2-0.1EPS (normalised) (c)-9.9-9.6-9.2-0.1Dividend per share (c)0.00.00.00.0Dividend payout ratio (%)0.00.00.00.0Dividend yield (%)0.00.00.00.0Growth ratios2009A2010F2011F2012FSales growthnanananaOperating cost growth15.2%8.6%14.2%naEBITA growth15.2%8.6%14.2%naEBITA growth14.5%8.5%13.0%naNorm. NPAT growth12.1%7.3%9.7%-99.3%Norm. NPAT growth (pre GW)12.3%-2.9%-4.3%naNorm. EPS growth (pre GW)12.3%-2.9%-4.3%naOperating performance2009A2010F2011F2012FAsset turnover (%)nanananaBITDA margin (%)nanananaNet debt (A\$m)-16.5-21.4-25.0-28.0Net debt/quity (%)-64.1-77.6-88.9-100.0Net interest/EBIT cover (x)14.416.615.3-2.0ROIC (%)-58.5-83.1-140.541.1Internal liquidity2009A2010F2011F2012FCurrent ratio (x)14.35.13.42.7Receivables turnover (x)<			-3.1	-3.6	9.6
EPS (cps) -9.9 -9.6 -9.2 -0.1 EPS (normalised) (c) -9.9 -9.6 -9.2 -0.1 Dividend per share (c) 0.0 0.0 0.0 0.0 Dividend payout ratio (%) 0.0 0.0 0.0 0.0 Dividend yield (%) 15.2% 8.6% 14.2% 89.7% EBITDA growth 14.5% 8.5% 13.0% na Norm. NPAT growth (pre GW) 22.1% 7.3% 9.7% -99.3% Norm. EPS growth (pre GW) 12.3% -2.9% -4.3% na Norm. EPS growth <t< td=""><td>Per share data</td><td>2009A</td><td>2010F</td><td>2011F</td><td>2012F</td></t<>	Per share data	2009A	2010F	2011F	2012F
EPS (normalised) (c) -9.9 -9.6 -9.2 -0.1 Dividend per share (c) 0.0 0.0 0.0 0.0 Dividend payout ratio (%) 0.0 0.0 0.0 0.0 Dividend payout ratio (%) 0.0 0.0 0.0 0.0 Dividend yield (%) 0.0 0.0 0.0 0.0 Growth ratios 2009A 2010F 2011F 2012F Sales growth na na na na Operating cost growth 15.2% 8.6% 14.2% 89.7% EBITDA growth 14.5% 8.5% 13.0% na EBIT growth 14.5% 8.5% 13.0% na Norm. NPAT growth (pre GW) 22.1% 7.3% 9.7% -99.3% Norm. EPS growth 12.3% -2.9% -4.3% na Norm. EPS growth 12.3% -2.9% -4.3% na Norm. EPS growth 12.3% -2.9% -4.3% na BIT margin (%) <t< td=""><td>No. shares</td><td></td><td>150.3</td><td></td><td></td></t<>	No. shares		150.3		
Dividend per share (c) 0.0 0.0 0.0 0.0 Dividend payout ratio (%) 0.0 0.0 0.0 0.0 0.0 Dividend yield (%) 0.0 0.0 0.0 0.0 0.0 0.0 Growth ratios 2009A 2010F 2011F 2012F Sales growth na na na na na Operating cost growth 15.2% 8.6% 14.2% 89.7% EBITDA growth 15.2% 8.6% 14.2% na EBIT growth 14.5% 8.5% 13.0% na Norm. NPAT growth (pre GW) 22.1% 7.3% 9.7% -99.3% Norm. EPS growth (pre GW) 12.3% -2.9% -4.3% na Norm. EPS growth 12.3% -2.9% -4.3% na Operating performance 2009A 2010F 2011F 2012F Asset turnover (%) 0.0 0.0 0.0 18.0 EBITDA margin (%) na na na <td></td> <td></td> <td></td> <td></td> <td></td>					
Dividend payout ratio (%) 0.0 0.0 0.0 0.0 Dividend yield (%) 0.0 0.0 0.0 0.0 0.0 Growth ratios 2009A 2010F 2011F 2012F Sales growth na na na na na na Operating cost growth 15.2% 8.6% 14.2% 89.7% EBITDA growth 15.2% 8.6% 14.2% na BITTA growth 14.5% 8.5% 13.0% na Norm. NPAT growth (pre GW) 22.1% 7.3% 9.7% -99.3% Norm. EPS growth (pre GW) 12.3% -2.9% -4.3% na Norm. EPS growth 12.3% -2.9% -4.3% na Operating performance 2009A 2010F 2011F 2012F Asset turnover (%) 0.0 0.0 0.0 18.0 EBITDA margin (%) na na na -0.4 Return on net assets (%) -39.3 -39.8 -44.2 <t< td=""><td></td><td></td><td></td><td></td><td></td></t<>					
Dividend yield (%) 0.0 0.0 0.0 0.0 Growth ratios 2009A 2010F 2011F 2012F Sales growth na na na na na Operating cost growth 15.2% 8.6% 14.2% 89.7% EBITDA growth 15.2% 8.6% 14.2% na EBITA growth 14.5% 8.5% 13.0% na BIT growth 14.5% 8.5% 13.0% na Norm. NPAT growth 22.1% 7.3% 9.7% -99.3% Norm. NPAT growth 22.1% 7.3% 9.7% -99.3% Norm. EPS growth 12.3% -2.9% -4.3% na Norm. EPS growth 12.3% -2.9% -4.3% na Operating performance 2009A 2010F 2011F 2012F Asset turnover (%) 0.0 0.0 0.0 18.0 EBITDA margin (%) na na na -4.2 Return on net assets (%)					
Sales growth na Operating cost growth 15.2% 8.6% 14.2% 89.7% EBITDA growth 15.2% 8.6% 14.2% na EBITA growth 14.5% 8.5% 13.0% na BEIT growth 14.5% 8.5% 13.0% na Nom. NPAT growth (pre GW) 22.1% 7.3% 9.7% -99.3% Norm. NPAT growth 22.1% 7.3% 9.7% -99.3% Norm. EPS growth 12.3% -2.9% -4.3% na Norm. NPAT growth 12.3% -2.9% -4.3% na Norm. NPAT growth 12.3% -2.9% -4.3% na Norm. NPAT growth 12.3% -2.9% -4.3% na na Norm. NPAT growth 12.3% -2.9% -4.3% na na Norm. NPAT growth 12.3% -2.9% -4.3% na					
Operating cost growth 15.2% 8.6% 14.2% 89.7% EBITDA growth 15.2% 8.6% 14.2% na EBITA growth 14.5% 8.5% 13.0% na EBIT growth 14.5% 8.5% 13.0% na BIT growth 14.5% 8.5% 13.0% na Norm. NPAT growth (pre GW) 22.1% 7.3% 9.7% -99.3% Norm. NPAT growth 22.1% 7.3% 9.7% -99.3% Norm. NPAT growth 12.3% -2.9% -4.3% na Norm. EPS growth 12.3% -2.9% -4.3% na Operating performance 2009A 2010F 2011F 2012F Asset turnover (%) 0.0 0.0 0.0 18.0 EBITDA margin (%) na na na -4.4 Return on net assets (%) -39.3 -39.8 -44.2 6.5 Net debt(A\$m) -16.5 -21.4 -25.0 -28.0 Net debt/equity (%)	Growth ratios	2009A	2010F	2011F	2012F
EBITDA growth 15.2% 8.6% 14.2% na EBITA growth 14.5% 8.5% 13.0% na EBIT growth 14.5% 8.5% 13.0% na Norm. NPAT growth 14.5% 8.5% 13.0% na Norm. NPAT growth 22.1% 7.3% 9.7% -99.3% Norm. NPAT growth 22.1% 7.3% 9.7% -99.3% Norm. EPS growth (pre GW) 12.3% -2.9% -4.3% na Operating performance 2009A 2010F 2011F 2012F Asset turnover (%) 0.0 0.0 0.0 18.0 EBITDA margin (%) na na na 6.8 Net profit margin (%) na na -4.4.2 6.5 Net debt (A\$m) -16.5 -21.4 -25.0 -28.0 Net debt/quity (%) -64.1 -77.6 -88.9 -100.0 Net interest/EBIT cover (x) 14.4 16.6 15.3 -2.0 ROIC (%)	•				
EBITA growth 14.5% 8.5% 13.0% na EBIT growth 14.5% 8.5% 13.0% na Norm. NPAT growth (pre GW) 22.1% 7.3% 9.7% -99.3% Norm. NPAT growth 22.1% 7.3% 9.7% -99.3% Norm. EPS growth (pre GW) 12.3% -2.9% -4.3% na Norm. EPS growth 12.3% -2.9% -4.3% na Operating performance 2009A 2010F 2011F 2012F Asset turnover (%) 0.0 0.0 0.0 18.0 EBITD amargin (%) na na na 6.8 Net profit margin (%) na na na 0.4 Return on net assets (%) -39.3 -39.8 -44.2 6.5 Net debt/equity (%) -64.1 -77.6 -88.9 -100.0 Net interest/EBIT cover (x) 14.4 16.6 15.3 -2.0 ROIC (%) -58.5 -83.1 -140.5 41.1 Inter					
EBIT growth 14.5% 8.5% 13.0% na Norm. NPAT growth (pre GW) 22.1% 7.3% 9.7% -99.3% Norm. NPAT growth 22.1% 7.3% 9.7% -99.3% Norm. NPAT growth 22.1% 7.3% 9.7% -99.3% Norm. EPS growth (pre GW) 12.3% -2.9% -4.3% na Norm. EPS growth 12.3% -2.9% -4.3% na Operating performance 2009A 2010F 2011F 2012F Asset turnover (%) 0.0 0.0 0.0 18.0 EBITDA margin (%) na na na 6.8 Net profit margin (%) na na na -0.4 Return on net assets (%) -39.3 -39.8 -44.2 6.5 Net debt/A\$m) -16.5 -21.4 -25.0 -28.0 Net debt/Quity (%) -64.1 -77.6 -88.9 -100.0 Net interest/EBIT cover (x) 14.4 16.6 15.3 -2.0	•				
Norm. NPAT growth (pre GW) 22.1% 7.3% 9.7% -99.3% Norm. NPAT growth 22.1% 7.3% 9.7% -99.3% Norm. EPS growth (pre GW) 12.3% -2.9% -4.3% na Norm. EPS growth 12.3% -2.9% -4.3% na Operating performance 2009A 2010F 2011F 2012F Asset turnover (%) 0.0 0.0 0.0 18.0 EBITDA margin (%) na na na 6.8 Net profit margin (%) na na na 6.4 Return on net assets (%) -39.3 -39.8 -44.2 6.5 Net debt/A§m) -16.5 -21.4 -25.0 -28.0 Net debt/Quity (%) -64.1 -77.6 -88.9 -100.0 Net interest/EBIT cover (x) 14.4 16.6 15.3 -2.0 ROIC (%) -58.5 -83.1 -140.5 41.1 Internal liquidity 2009A 2010F 2011	-				
Norm. EPS growth (pre GW) 12.3% -2.9% -4.3% na Norm. EPS growth 12.3% -2.9% -4.3% na Operating performance 2009A 2010F 2011F 2012F Asset turnover (%) 0.0 0.0 0.0 18.0 EBITDA margin (%) na na na 11.9 EBIT margin (%) na na na 6.8 Net profit margin (%) na na na -4.4 Return on net assets (%) -39.3 -39.8 -44.2 6.5 Net debt (A\$m) -16.5 -21.4 -25.0 -28.0 Net debt/equity (%) -64.1 -77.6 -88.9 -100.0 Net interest/EBIT cover (x) 14.4 16.6 15.3 -2.0 ROIC (%) -58.5 -83.1 -140.5 41.1 Internal liquidity 2009A 2010F 2011F 2012F Current ratio (x) 14.3 5.1 3.4 2.7 Receivables t					
Norm. EPS growth 12.3% -2.9% -4.3% na Operating performance 2009A 2010F 2011F 2012F Asset turnover (%) 0.0 0.0 0.0 18.0 EBITDA margin (%) na na na 11.9 EBIT margin (%) na na na 6.8 Net profit margin (%) na na na 6.8 Net profit margin (%) na na na 0.4 Return on net assets (%) -39.3 -39.8 -44.2 6.5 Net debt (A\$m) -16.5 -21.4 -25.0 -28.0 Net debt/equity (%) -64.1 -77.6 -88.9 -100.0 Net interest/EBIT cover (x) 14.4 16.6 15.3 -2.0 ROIC (%) -58.5 -83.1 -140.5 41.1 Internal liquidity 2009A 2010F 2011F 2012F Current ratio (x) 14.3 5.1 3.4 2.7 Receivables turnover (x) </td <td></td> <td>22.1%</td> <td>7.3%</td> <td>9.7%</td> <td>-99.3%</td>		22.1%	7.3%	9.7%	-99.3%
Operating performance 2009A 2010F 2011F 2012F Asset turnover (%) 0.0 0.0 0.0 18.0 EBITDA margin (%) na na na 11.9 EBIT margin (%) na na na 14.9 Return on net assets (%) -39.3 -39.8 -44.2 6.5 Net debt (A\$m) -16.5 -21.4 -25.0 -28.0 Net debt/equity (%) -64.1 -77.6 -88.9 -100.0 Net interest/EBIT cover (x) 14.4 16.6 15.3 -2.0 ROIC (%) -58.5 -83.1 -140.5 41.1 Internal liquidity 2009A 2010F 2011F 2012F Current ratio (x) 14.3 5.1 3.4 2.7 Receivables turnover (x) na 0.0 0.0 55.2	• • •				na
Asset turnover (%) 0.0 0.0 0.0 18.0 EBITDA margin (%) na na na 11.9 EBIT margin (%) na na na 11.9 EBIT margin (%) na na na 11.9 EBIT margin (%) na na na 6.8 Net profit margin (%) na na na -0.4 Return on net assets (%) -39.3 -39.8 -44.2 6.5 Net debt (ASm) -16.5 -21.4 -25.0 -28.0 Net debt/equity (%) -64.1 -77.6 -88.9 -100.0 Net interest/EBIT cover (x) 14.4 16.6 15.3 -2.0 ROIC (%) -58.5 -83.1 -140.5 41.1 Internal liquidity 2009A 2010F 2011F 2012F Current ratio (x) 14.3 5.1 3.4 2.7 Receivables turnover (x) na 0.0 0.0 55.2	Norm. EPS growth	12.3%	-2.9%	-4.3%	na
EBITDA margin (%) na na na na na 11.9 EBIT margin (%) na na na na 6.8 Net profit margin (%) na na na -0.4 Return on net assets (%) -39.3 -39.8 -44.2 6.5 Net debt (A\$m) -16.5 -21.4 -25.0 -28.0 Net debt/equity (%) -64.1 -77.6 -88.9 -100.0 Net interest/EBIT cover (x) 14.4 16.6 15.3 -2.0 ROIC (%) -58.5 -83.1 -140.5 41.1 Internal liquidity 2009A 2010F 2011F 2012F Current ratio (x) 14.3 5.1 3.4 2.7 Receivables turnover (x) na 0.0 0.0 55.2					
EBIT margin (%) na					
Net profit margin (%) na na na na na -0.4 Return on net assets (%) -39.3 -39.8 -44.2 6.5 Net debt (A\$m) -16.5 -21.4 -25.0 -28.0 Net debt/equity (%) -64.1 -77.6 -88.9 -100.0 Net interest/EBIT cover (x) 14.4 16.6 15.3 -2.0 ROIC (%) -58.5 -83.1 -140.5 41.1 Internal liquidity 2009A 2010F 2011F 2012F Current ratio (x) 14.3 5.1 3.4 2.7 Receivables turnover (x) na 0.0 0.0 55.2					
Net debt (A\$m) -16.5 -21.4 -25.0 -28.0 Net debt/equity (%) -64.1 -77.6 -88.9 -100.0 Net interest/EBIT cover (x) 14.4 16.6 15.3 -2.0 ROIC (%) -58.5 -83.1 -140.5 41.1 Internal liquidity 2009A 2010F 2011F 2012F Current ratio (x) 14.3 5.1 3.4 2.7 Receivables turnover (x) na 0.0 0.0 55.2	0 ()				
Net debt/equity (%) -64.1 -77.6 -88.9 -100.0 Net interest/EBIT cover (x) 14.4 16.6 15.3 -2.0 ROIC (%) -58.5 -83.1 -140.5 41.1 Internal liquidity 2009A 2010F 2011F 2012F Current ratio (x) 14.3 5.1 3.4 2.7 Receivables turnover (x) na 0.0 0.0 55.2					
Net interest/EBIT cover (x) 14.4 16.6 15.3 -2.0 ROIC (%) -58.5 -83.1 -140.5 41.1 Internal liquidity 2009A 2010F 2011F 2012F Current ratio (x) 14.3 5.1 3.4 2.7 Receivables turnover (x) na 0.0 0.0 55.2					
ROIC (%) -58.5 -83.1 -140.5 41.1 Internal liquidity 2009A 2010F 2011F 2012F Current ratio (x) 14.3 5.1 3.4 2.7 Receivables turnover (x) na 0.0 0.0 55.2					
Current ratio (x) 14.3 5.1 3.4 2.7 Receivables turnover (x) na 0.0 0.0 55.2					
Current ratio (x) 14.3 5.1 3.4 2.7 Receivables turnover (x) na 0.0 0.0 55.2	Internal liquidity	20004	2010F	20115	2012F
Receivables turnover (x) na 0.0 0.0 55.2					
Payables turnover (x) na 8.3 7.9 12.5		na	0.0	0.0	55.2
	Payables turnover (x)	na	8.3	7.9	12.5

Source: Company data, RBS estimates

Recommendation structure

Absolute performance, short term (trading) recommendation: A Trading Buy recommendation implies upside of 5% or more and a Trading Sell indicates downside of 5% or more. The trading recommendation time horizon is 0-60 days. For Australian coverage, a Trading Buy recommendation implies upside of 5% or more from the suggested entry price range, and a Trading Sell recommendation time horizon is 0-60 days.

Absolute performance, long term (fundamental) recommendation: The recommendation is based on implied upside/downside for the stock from the target price. A Buy/Sell implies upside/downside of 10% or more and a Hold less than 10%. For UK-based Investment Funds research the recommendation structure is not based on upside/downside to the target price. Rather it is the subjective view of the analyst based on an assessment of the resources and track record of the fund management company. For listed property trusts (LPT) or real estate investment trusts (REIT) the recommendation is based upon the target price plus the dividend yield, is total return.

Performance parameters and horizon: Given the volatility of share prices and our pre-disposition not to change recommendations frequently, these performance parameters should be interpreted flexibly. Performance in this context only reflects capital appreciation and the horizon is 12 months. Sector relative to market: The sector view relative to the market is the responsibility of the strategy team. Overweight/Underweight/Ingles upside/downside of 10% or more and Neutral implies less than 10% upside/downside. Target price: The target price is the level the stock should currently trade at if the market were to accept the analyst's view of the stock and if the necessary catalysts were in place to effect this change in perception within the performance horizon. In this way, therefore, the target price abstracts from the need to take a view on the market or sector. If it is felt that the catalysts are not fully in place to effect a re-rating of the stock to its warranted value, the target price will differ from 'fair' value.

Distribution of recommendations

The tables below show the distribution of ABN AMRO's recommendations (both long term and trading). The first column displays the distribution of recommendations globally and the second column shows the distribution for the region. Numbers in brackets show the percentage for each category where ABN AMRO has an investment banking relationship.

Long Term recommendations (as at 03 Dec 2009)

Trading recommendations (as at 03 Dec 2009)

	Global total (IB%)	Asia Pacific total (IB%)
Buy	607 (10)	390 (1)
Add	0 (0)	0 (0)
Hold	401 (6)	222 (0)
Reduce	0 (0)	0 (0)
Sell	116 (0)	72 (0)
Total (IB%)	1124 (7)	684 (0)

Global total (IB%)Asia Pacific total (IB%)
(IB%)Trading Buy4 (0)Trading Sell1 (0)Total (IB%)5 (0)

Source: ABN AMRO

Source: ABN AMRO


Valuation and risks to target price

CSL Ltd (RIC: CSL.AX, Rec: Hold, CP: A\$31.76, TP: A\$36.30): Our target price is set at a premium to our blended DCF, PE, EV/EBITDA valuation to account for potential upside from a possible global pharma bid. Downside risks to our target price relate to irrational industry behaviour leading to potential oversupply of IVIG, which in turn could lead to price weakness, and lower-than-expected HPV revenues from Merck. Upside could come from IVIG demand in Alzheimer's disease.

Clinuvel Pharmaceuticals (RIC: CUV.AX, Rec: Buy, CP: A\$0.300, TP: A\$0.85): Our valuation of CUV is based on a discounted cash flow model, from which we derive our target price. Upside risks include the faster-than-expected progression to production of CUV's photoprotective technology, while downside risks include any delay or failure to progress clinical trials. Mesoblast (RIC: MSB.AX, Rec: Buy, CP: A\$1.410, TP: A\$1.21): Our valuation of MSB is based on a discounted cash flow model, from which we derive our target price. Upside risks include the faster-than-expected progression to production of MSB's MPC technology, while downside risks include the lack of scalability of the manufacturing process.

(PA) Previous Analyst (CA) Current Analyst (NC) Not Under Coverage

CSL Ltd coverage data





Trading recommendation history (as at 03 Dec 2009)

•		
Date	Rec	Analyst
01 May 2009	n/a	CA
17 Mar 2009	Trading Buy	CA
13 Jan 2008	Trading Buy	CA

Source: ABN AMRO


(B)uy (A)dd (H)old (R)educe (S)ell (PA) F Dr David Stanton started covering this stock on 10 Nov 04 New recommendation structure from 7 November 2005 Source: ABN AMRO





Dr David Stanton started covering this stock on 2 Aug 07 New recommendation structure from 7 November 2005 Source: ABN AMRO

Mesoblast coverage data



Dr David Stanton started covering this stock on 2 Aug 07 New recommendation structure from 7 November 2005 Source: ABN AMRO

Regulatory disclosures

Subject companies: CSL.AX, CUV.AX, MSB.AX

ABN AMRO Morgans Limited was a broker to the placement of shares by CSL Limited in August 2008 and received fees in this regard.: CSL.AX

Global disclaimer

© Copyright 2009 ABN AMRO Bank N.V. and affiliated companies ("ABN AMRO"). All rights reserved.

This material was prepared by the ABN AMRO affiliate named on the cover or inside cover page. It is provided for informational purposes only and does not constitute an offer to sell or a solicitation to buy any security or other financial instrument. While based on information believed to be reliable, no guarantee is given that it is accurate or complete. While we endeavour to update on a reasonable basis the information and opinions contained herein, there may be regulatory, compliance or other reasons that prevent us from doing so. The opinions, forecasts, assumptions, estimates, derived valuations and target price(s) contained in this material are as of the date indicated and are subject to change at any time without prior notice. The investments referred to may not be suitable for the specific investment objectives, financial situation or individual needs of recipients and should not be relied upon in substitution for the exercise of independent judgement. The stated price of any securities mentioned herein is as of the date indicated and is not a representation that any transaction can be effected at this price. Neither ABN AMRO or other persons shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way from the information contained in this material is for the use of intended recipients only and the contents may not be reproduced, redistributed, or copied in whole or in part for any purpose without ABN AMRO's prior express consent. In any jurisdiction in which distribution to private/retail customers would require registration or licensing of the distributor does not currently have, this document is intended solely for distribution to professional and institutional investors.

Australia: Any report referring to equity securities is distributed in Australia by RBS Equities (Australia) Limited (ABN 84 002 768 701, AFS Licence 240530) ("RBS Equities"), a participant of the ASX Group. Research produced by Craigs Investment Partners Limited is distributed outside New Zealand by RBS Equities and its associated companies under the strategic alliance between the two groups of companies. Any report referring to fixed income securities is distributed in Australia by ABN AMRO Bank NV (Australia Branch) (ABN 84 079 478 612, AFS Licence 238266). Australian investors should note that this document was prepared for wholesale investors only.

Brazil: This document was not elaborated by securities analysts registered at Comissao de Valores Mobiliarios - CVM. Investors resident in Brazil who receive this report should rely only on research prepared by research analysts registered at CVM. In addition to other representations contained in this report, research analysts who prepared this report state that the views expressed and attributed to them accurately reflect solely and exclusively their personal opinions about the subject securities and issuers and/or other subject matter as appropriate, having such opinion(s) been produced freely and independently from any party, including from The Royal Bank of Scotland or any of its affiliates.

Canada: The securities mentioned in this material are available only in accordance with applicable securities laws and many not be eligible for sale in all jurisdictions. Persons in Canada requiring further information should contact their own advisors.

EA: This material constitutes "investment research" for the purposes of the Markets in Financial Instruments Directive and as such contains an objective or independent explanation of the matters contained in the material. Any recommendations contained in this document must not be relied upon as investment advice based on the recipient's personal circumstances. In the event that further clarification is required on the words or phrases used in this material, the recipient is strongly recommended to seek independent legal or financial advice.

Denmark: ABN AMRO Bank N.V. is authorised and regulated in the Netherlands by De Nederlandsche Bank. In addition, ABN AMRO Bank N.V., Copenhagen Branch is subject to local supervision by Finanstilsynet, the Danish Financial Supervisory Authority. All analysts located in Denmark follow the recommendations from the Danish Securities Dealers Association. Finland: ABN AMRO Bank N.V. is authorised and regulated in the Netherlands by De Nederlandsche Bank. In addition, ABN AMRO Bank N.V., Helsinki Branch is subject to local supervision by Rahoitustarkastus, the Finnish Financial Supervision Authority.

Hong Kong: This document is being distributed in Hong Kong by, and is attributable to, RBS Asia Limited which is regulated by the Securities and Futures Commission of Hong Kong.

India: Shares traded on stock exchanges within the Republic of India may only be purchased by different categories of resident Indian investors, Foreign Institutional Investors registered with The Securities and Exchange Board of India ("SEBI") or individuals of Indian national origin resident outside India called Non Resident Indians ("NRIs"). Any recipient of this document wanting additional information or to effect any transaction in Indian securities or financial instrument mentioned herein must do so by contacting a representative of RBS Equities (India) Limited. RBS Equities (India) Limited is a subsidiary of ABN AMRO Bank NV.

Indonesia: PT. RBS Asia Securities Indonesia is a subsidiary undertaking of The Royal Bank of Scotland Group plc.

Italy: Persons in Italy requiring further information should contact ABN AMRO Bank N.V. Milan Branch.

Japan: This report is being distributed in Japan by ABN AMRO Securities Japan Ltd to institutional investors only.

Malaysia: ABN AMRO research, except for economics and FX research, is not for distribution or transmission into Malaysia.

New Zealand: This document is distributed in New Zealand by Craigs Investment Partners Limited, an NZX accredited firm. Craigs Investment Partners Limited and/or its partners and employees may, from time to time, have a financial interest in respect of some or all of the matters discussed.

Russia: The Russian securities market is associated with several substantial risks, legal, economic and political, and high volatility. There is a relatively high measure of legal uncertainty concerning rights, duties and legal remedies in the Russian Federation. Russian laws and regulations governing investments in securities markets may not be sufficiently developed or may be subject to inconsistent or arbitrary interpretation or application. Russian securities are often not issued in physical form and registration of ownership may not be subject to a centralised system. Registration of ownership of certain types of securities may not be subject to standardised procedures and may even be effected on an ad hoc basis. The value of investments in Russian securities may be affected by fluctuations in available currency rates and exchange control regulations.

Singapore: Any report referring to equity securities is distributed in Singapore by The Royal Bank of Scotland Asia Securities (Singapore) Pte Limited (RCB Regn No. 198703346M) to clients who fall within the description of persons in Regulation 49 of the Securities and Futures (Licensing and Conduct of Business) Regulations and Regulations 34 and 35 of the Financial Advisers Regulations. Investors should note that this material was prepared for accredited investors only. Recipients who do not fall within the description of persons under Regulation 49 of the Securities and Futures (Licensing and Conduct of Business) Regulations 34 and 35 of the Financial Advisers Regulations should seek the advice of their independent financial advisor prior to taking any investment decision based on this document or for any necessary explanation of its contents. The Royal Bank of Scotland Asia Securities (Singapore) Pte Limited is a subsidiary undertaking of The Royal Bank of Scotland Group plc.

Sweden: ABN AMRO Bank N.V. is authorised and regulated in the Netherlands by De Nederlandsche Bank. In addition, ABN AMRO Bank N.V., Stockholm Branch is subject to local supervision by the Swedish Financial Supervisory Authority.

Thailand: Pursuant to an agreement with Asia Plus Securities Public Company Limited (APS), reports on Thai securities published out of Thailand are prepared by APS but distributed outside Thailand by ABN AMRO Bank NV and affiliated companies. Responsibility for the views and accuracy expressed in such documents belongs to APS.

United Kingdom: All research is distributed by ABN AMRO Bank NV, London Branch, which is authorised by De Nederlandsche Bank. The investments and services contained herein are not available to private customers in the United Kingdom.

UAE and Qatar: This report is produced by ABN AMRO N.V and is being distributed to professional and institutional investors only in the United Arab Emirates and Qatar in accordance with the regulatory requirements governing the distribution of investment research in these jurisdictions.

United States: Except for any documents relating to foreign exchange, FX or global FX, distribution of this document in the United States or to US persons is intended to be solely to major institutional investors as defined in Rule 15a-6(a)(2) under the US Securities Act of 1934. All US persons that receive this document by their acceptance thereof represent and agree that they are a major institutional investor and understand the risks involved in executing transactions in securities. Any US recipient of this document wanting additional information or to effect any transaction in any security or financial instrument mentioned herein, must do so by contacting a registered representative of to RBS Securities Inc, 600 Washington Blvd, Stamford, CT 06901, +1 203 897 2700.

- Material means all research information contained in any form including but not limited to hard copy, electronic form, presentations, e-mail, SMS or WAP. The Royal Bank of Scotland plc is authorised and regulated in the UK by the Financial Services Authority.

The research analysts responsible for the content of this research report certify that: (1) the views expressed and attributed to the research analysts or analysts in the research report accurately reflect their personal opinion(s) about the subject securities and issuers and/or other subject matter as appropriate; and, (2) no part of his or her compensation was, is or will be directly or indirectly related to the specific recommendations or views contained in this research report. On a general basis, the efficacy of recommendations is a factor in the performance appraisals of analysts.

For a discussion of the valuation methodologies used to derive our price targets and the risks that could impede their achievement, please refer to our latest published research on those stocks at www.abnamroresearch.com.

Disclosures regarding companies covered by ABN AMRO group can be found on ABN AMRO's research website at www.abnamroresearch.com.

ABN AMRO's policy on managing research conflicts of interest can be found at https://www.abnamroresearch.com/Disclosure/Disclosure/AspX?MI=5.

Should you require additional information please contact the relevant ABN AMRO research team or the author(s) of this report.